US20050019379A1 - Wipe and methods for improving skin health - Google Patents

Wipe and methods for improving skin health Download PDF

Info

Publication number
US20050019379A1
US20050019379A1 US10/624,186 US62418603A US2005019379A1 US 20050019379 A1 US20050019379 A1 US 20050019379A1 US 62418603 A US62418603 A US 62418603A US 2005019379 A1 US2005019379 A1 US 2005019379A1
Authority
US
United States
Prior art keywords
product
wipe
set forth
botanical compound
skin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US10/624,186
Inventor
Beth Lange
David Koenig
Christine Schneider
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kimberly Clark Worldwide Inc
Original Assignee
Kimberly Clark Worldwide Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kimberly Clark Worldwide Inc filed Critical Kimberly Clark Worldwide Inc
Priority to US10/624,186 priority Critical patent/US20050019379A1/en
Assigned to KIMBERLY-CLARK WORLDWIDE, INC. reassignment KIMBERLY-CLARK WORLDWIDE, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: KOENIG, DAVID W., LANGE, BETH A., SCHNEIDER, CHRISTINE L.
Publication of US20050019379A1 publication Critical patent/US20050019379A1/en
Application status is Abandoned legal-status Critical

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K8/00Cosmetics or similar toilet preparations
    • A61K8/02Cosmetics or similar toilet preparations characterised by special physical form
    • A61K8/0208Tissues; Wipes; Patches
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K8/00Cosmetics or similar toilet preparations
    • A61K8/18Cosmetics or similar toilet preparations characterised by the composition
    • A61K8/96Cosmetics or similar toilet preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97Cosmetics or similar toilet preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION, OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS, OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS, OR SURGICAL ARTICLES
    • A61L15/00Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
    • A61L15/16Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
    • A61L15/40Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing ingredients of undetermined constitution or reaction products thereof, e.g. plant or animal extracts
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILET PREPARATIONS
    • A61Q17/00Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
    • A61Q17/005Antimicrobial preparations
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILET PREPARATIONS
    • A61Q19/00Preparations for care of the skin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F13/00Bandages or dressings; Absorbent pads
    • A61F13/15Absorbent pads, e.g. sanitary towels, swabs or tampons for external or internal application to the body; Supporting or fastening means therefor; Tampon applicators
    • A61F13/84Accessories, not otherwise provided for, for absorbent pads
    • A61F13/8405Additives, e.g. for odour, disinfectant or pH control
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K2800/00Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/70Biological properties of the composition as a whole

Abstract

The present invention relates to methods and products, such as wet wipes and absorbent articles, that are capable of imparting a health benefit when used in the intended fashion. More specifically, the products described herein comprise one or more botanical compounds, which are capable of selectively controlling the balance of flora on the skin. The compounds may enhance the adherence of healthy flora to the surface of skin or mucosa, inhibit the growth of problem flora on or around the skin surface, or inhibit the adherence of problem flora to the surface of skin or mucosa, or any combination thereof.

Description

    BACKGROUND OF THE INVENTION
  • The present invention relates to personal care products, such as wipes and absorbent articles, that are capable of providing a skin health benefit to the user. More particularly, the present invention relates to wet wipes comprising at least one botanical compound that selectively controls the growth and/or adherence of flora on the skin. The botanical compounds described herein and suitable for incorporation into a wipe or absorbent article may selectively promote the adherence of healthy flora to the surface of skin or mucosa, selectively inhibit the growth of problem flora on or around the skin surface, selectively inhibit the adherence of problem flora to the surface of skin or mucosa, or provide multiple combinations of these effects.
  • A variety of flora, both beneficial and pathogenic, may be found on the skin at any given time. Problem flora, such as pathogenic bacteria and yeast, have been associated with numerous ailments, including skin infections, diaper rash, urinary or vaginal infections, and malodors, and are associated with various irritants, such as proteases, lipases, carbohydrases, lipopolysaccharides (“LPS”), volatile organic compounds (“VOCs”), and other bio-molecules. In contrast, healthy bacteria attach to the skin, and may provide a variety of benefits, including playing a role in preventing pathogenic organisms from colonizing or growing.
  • The disruption in the protection of healthy flora may result in the colonization of other organisms, which in turn may cause irritation, infection, and diseases on or near the skin surface. One example of a healthy bacterium is Lactobacillus acidophilius, which colonizes the vaginal epithelium during child-bearing years, and inhibits the growth of pathogens. Another skin bacterium which can have positive health attributes is Staphylococcus epidermidis. S. epidermidis is a normal microbial inhabitant of human skin. In most cases, strains of S. epidermidis are nonpathogenic and play a protective role in their host. For instance, S. epidermidis appears to prevent colonization of the skin by dermatophytic fungi, and may alter the production of irritating metabolites. In limited circumstances, S. epidermidis, however, can become an opportunistic pathogen by spreading into the blood through breaks in skin barriers. Individuals most susceptible to S. epidermidis infection are intravenous drug users, newborns, elderly, and those using catheters or other artificial appliances. Regardless, S. epidermidis is generallly regarded as a bacteria that provides a health benefit.
  • In contrast, an example of a common pathogenic flora is Candida albicans. When in yeast form, C. albicans naturally inhabits the human digestive tract, and is a normal part of bowel flora. However, under certain conditions, such as a weakened immune system, a high sugar diet, or improper pH in the digestive system, among others, C. albicans may shift from the yeast stage, to an invasive mycelial fungal form. The mycelial fungal form of C. albicans binds readily to the skin and mucus membranes, and is associated with a wide variety of infections, including vaginal yeast infections, oral infections, and diaper rash.
  • Other common pathogenic flora include Pseudomonas aeruginosa, Proteus mirabilis, and Escherichia coli. Like C. albicans, E. coli naturally inhabit the human gastro-intestinal tract. However, E. coli can be pathogenic, and are responsible for several types of infections in humans, including urinary tract infections. For example, E. coli can colonize from the feces or perineal region, and ascend the urinary tract to the bladder, causing infection and irritation.
  • P. aeruginosa is an opportunistic pathogen of humans, and is resistant to many antibiotics. P. aeruginosa may infect almost any type of compromised tissue, and can cause a variety of infections, including urinary tract infections, respiratory system infections, dermatitis, soft tissue infections, and bacteremia, as well as a variety of systemic infections, particularly in immunosuppressed patients.
  • P. mirabilis is a Gram negativie rod that is widely distributed in nature and easily isolated in the feces of most animals, but is hardly ever found in high numbers unless the normal intestinal microflora is altered. P. mirabilis can cause invasive diarrhea and severe infections of the upper urinary tract, and has also been implicated in infections of blood and wounds.
  • To date, skin cleaning products, such as wet wipes and dry wipes, have primarily cleaned the skin by attempting to remove and/or kill all flora present on the skin, regardless of whether the flora are potentially beneficial or potentially harmful. For example, numerous commercially available wet wipes comprise at least one antimicrobial compound, such as an organic acid, which is typically used in combination with a surfactant to kill flora on the skin surface. Although typically effective in killing flora located on the skin surface, the antimicrobial wipe kills all flora and does not, and cannot, distinguish between “good” and “bad” flora.
  • Based on the foregoing, it would be desirable to provide a skin health benefit for inhibiting the growth or adherence to the skin of problem flora, while maintaining, or even enhancing the adherence of healthy flora. Products, such as wipes or absorbent articles, that comprise one or more compounds capable of selectively controlling the growth and/or adherence of flora to the skin would thus be desirable, and could impart a beneficial health effect to the user.
  • SUMMARY OF THE INVENTION
  • The present invention relates to products and methods for selectively controlling the balance of flora on the skin. More specifically, the present invention relates to products such as wet wipes or absorbent articles containing one or more botanical compounds that promote the adherence of healthy flora to the surface of skin or mucosa, inhibit the growth of problem flora on or around the skin surface, inhibit the adherence of problem flora to the surface of skin or mucosa, or any combination thereof.
  • Briefly, in one embodiment, the present invention is directed to a product for promoting the adherence of Lactobacillus acidophilus to the surface of skin or mucosa. The product comprises a substrate and a botanical compound that is capable of increasing the adherence of Lactobacillus acidophilus by at least about 50%, as defined herein.
  • In another embodiment, the present invention is directed to a product for promoting the adherence of Staphlococcus epidermidis to the surface of skin. The product comprises a substrate and a botanical compound that is capable of increasing the adherence of Staphlococcus epidermidis by at least about 50%, as defined herein.
  • The present invention also relates to products, such as wipes or absorbent aritcles, for inhibiting the adherence of problem organisms to the surface of skin or mucosa. The product comrises a substrate, such as a fibrous wipe substrate or an absorbent substrate, and a botanical compound that is capable of inhibiting the adherence of a problem organism by at least about 50%, as defined herein. The problem organism may be Candida albicans, Proteus mirabilis, Pseudomonas aeruginosa, Staphlococcus epidermidis, or a combination thereof.
  • The present invention is also directed to a product for inhibiting growth of one or more bacteria or yeast on or around the skin's surface. The product comprises a botanical compound suitable for inhibiting the growth of Candida albicans, Proteus mirabilis, Pseudomonas aeruginosa, and/or Staphlococcus epidermidis.
  • Furthermore, the present invention relates to products comprising a substrate, such as a fibrous wipe substrate or absorbent substrate, and a combination of two or more botanical compounds that may provide differing beneficial effects. In one embodiment, the product comprises a first botanical compound that promotes the adherence of Lactobacillus acidophilus to the surface of skin or mucosa by at least about 50%, and a second botanical compound that inhibits the adherence of at least one organism to the surface of skin or mucosa by at least about 50%, the organism selected from the group consisting of Candida albicans, Proteus mirabilis, Pseudomonas aeruginosa, and Staphylococcus epidermidis.
  • In another embodiment, the product comprises a first botanical compound that promotes the adherence of Lactobacillus acidophilus to the surface of skin or mucosa by at least about 50%, and a second botanical compound that promotes the adherence of Staphylococcus epidermidis to the surface of skin by at least about 50%.
  • In yet another embodiment, the product comprises a first botanical compound that inhibits the adherence of at least one organism to the surface of skin or mucosa by at least about 50%, the organism selected from the group consisting of Candida albicans, Proteus mirabilis, Pseudomonas aeruginosa, and Staphylococcus epidermidis, and a second botanical compound that inhibits the growth of at least one organism on or around the skin surface, the organism selected from the group consisting of Candida albicans, Proteus mirabilis, Pseudomonas aeruginosa, and Staphylococcus epidermidis, wherein the second botanical compound has an IC50 value of about 5% or less for Candida albicans, Proteus mirabilis, Pseudomonas aeruginosa, or Staphylococcus epidermidis.
  • The present invention also relates to a method for promoting the adherence of Lactobacillus acidophilus to the surface of skin or mucosa, and to a wet wipe for promoting the adherence of Lactobacillus acidophilus to the surface of skin or mucosa.
  • DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
  • In accordance with the present invention, it has been discovered that certain bio-compounds, such as specific botanical extracts or botanical actives, can be utilized in combination with personal care products, such as wipes or absorbent articles, to impart a skin health benefit by selectively controlling the balance of flora on the skin. More specifically, it has been discovered that certain botanical compounds may provide at least one of the following benefits when used in combination with a wipe substrate or absorbent article and contacted with the skin or mucosa: (i) promote the adherence of healthy flora to the surface of skin or mucosa, (ii) inhibit the growth of problem flora on the skin surface, and/or (iii) inhibit the adherence of problem flora to the surface of skin or mucosa. By introducing a botanical compound, or a combination of botanical compounds having one or more of these characteristics into a solution that is used in combination with a wipe or absorbent article substrate, it is possible to selectively control the growth and adherence of various bacteria and yeast on the skin.
  • The personal care products of the present invention contain at least one botanical compound. As used herein, the term “botanical compound” is meant to include bio-compounds such as botanical extracts and/or botanical actives, as well as essential oils and herbs. The botanical compound is capable of improving the health of skin contacted by the wipe or absorbent article during normal use by selectively controlling the growth and/or adherence of flora to the skin. Numerous personal care products can be used in combination with the botanical compounds described herein in accordance with the present invention to impart a skin health benefit to the user. For example, one or more of the botanical compounds described herein can be used in combination with wipes, such as wet wipes, hand wipes, face wipes, cosmetic wipes, household wipes, dry wipes, feminine wipes, and the like, to selectively control the balance of flora on the skin by reducing the growth or adherence of problem flora, such as pathogenic bacteria or yeast, to the skin, and/or promoting the adherence of beneficial flora, such as healthy bacteria, to the surface of skin or mucosa.
  • In addition, one or more of the botanical compounds described herein can be used in combination with an absorbent article such as diapers, training pants, adult incontinence garments, feminine napkins, tampons, interlabial pads, facial tissue, wound management products, paper towels, and bath tissue. As will be understood by one skilled in the art, the botanical compound may be directly impregnated on the wipe or absorbent substrate, or may be in a liquid formulation or ointment used with the wipe or absorbent article.
  • Although discussed primarily in combination with a wipe substrate, it should be understood that the botanical compounds can also be used in combination with other nuerous absorbent products described above. Materials suitable for use as the substrate of the wipe are well known to those skilled in the art, and typically include a fibrous sheet material, which may be either woven or nonwoven. For example, the wipes incorporating the botanical compounds described herein to improve skin health may include nonwoven fibrous sheet materials, which include meltblown, coform, air-laid, bonded-carded web materials, hydroentangled materials, and combinations thereof. Such materials can be comprised of synthetic or natural fibers, or a combination thereof. Typically, wipes define a basis weight of from about 25 to about 120 grams per square meter and desirably from about 40 to about 90 grams per square meter.
  • In a particular embodiment, the wipes incorporating the botanical compounds described herein comprise a coform basesheet of polymeric microfibers and cellulosic fibers having a basis weight of from about 60 to about 80 grams per square meter and desirably about 75 grams per square meter. Such coform basesheets are manufactured generally as described in U.S. Pat. No. 4,100,324, which is incorporated by reference. Typically, such coform basesheets comprise a gas-formed matrix of thermoplastic polymeric meltblown microfibers, such as, for example, polypropylene microfibers, and cellulosic fibers, such as, for example, wood pulp fibers.
  • The relative percentages of the polymeric microfibers and cellulosic fibers in the coform basesheet can vary over a wide range depending upon the desired characteristics of the wet wipes. For example, the coform basesheet may comprise from about 20 to about 100 weight percent, desirably from about 20 to about 60 weight percent, and more desirably from about 30 to about 40 weight percent of the polymeric microfibers based on the dry weight of the coform basesheet being used to provide the wipes.
  • Alternatively, the wipes incorporating the botanical compounds described herein can comprise a composite, which includes multiple layers of materials such as those described in U.S. Pat. No. 6,028,018, which is incorporated by reference. For example, the wipes may include a three layer composite, which includes an elastomeric film or meltblown layer between two coform layers as described above. In such a configuration, the coform layers may define a basis weight of from about 15 to about 30 grams per square meter and the elastomeric layer may include a film material such as a polyethylene metallocene film.
  • As mentioned above, one type of wipe suitable for use in combination with the botanical compounds described herein to improve skin health include wet wipes, which, in addition to the wipe substrate, comprise a liquid solution or formulation. The liquid solution or formulation can be any liquid, which can be absorbed into the wet wipe basesheet and may include any suitable components, which provide the desired wiping properties. For example, the components may include water, emollients, surfactants, fragrances, preservatives, chelating agents, pH buffers, or combinations thereof as are well known to those skilled in the art. Further, the liquid may also contain lotions, medicaments, and/or antimicrobials.
  • The amount of liquid contained within each wet wipe may vary depending upon the type of material being used to provide the wet wipe, the type of liquid being used, the type of container being used to store the wet wipes, and the desired end use of the wet wipe. Generally, each wet wipe can contain from about 150 to about 600 weight percent and desirably from about 250 to about 450 weight percent liquid based on the dry weight of the wipe for improved wiping. In a particular aspect, the amount of liquid contained within the wet wipe is from about 300 to about 400 weight percent and desirably about 330 weight percent based on the dry weight of the wet wipe. If the amount of liquid is less than the above-identified ranges, the wet wipe may be too dry and may not adequately perform. If the amount of liquid is greater than the above-identified ranges, the wet wipe may be oversaturated and soggy and the liquid may pool in the bottom of the container.
  • Each wet wipe is generally rectangular in shape and may have any suitable unfolded width and length. For example, the wet wipe may have an unfolded length of from about 2.0 to about 80.0 centimeters and desirably from about 10.0 to about 25.0 centimeters and an unfolded width of from about 2.0 to about 80.0 centimeters and desirably from about 10.0 to about 25.0 centimeters. Typically, each individual wet wipe is arranged in a folded configuration and stacked one on top of the other to provide a stack of wet wipes. Such folded configurations are well known to those skilled in the art and include c-folded, z-folded, quarter-folded configurations and the like. The stack of folded wet wipes may be placed in the interior of a container, such as a plastic tub, to provide a package of wet wipes for eventual sale to the consumer. Alternatively, the wet wipes may include a continuous strip of material which has perforations between each wipe and which may be arranged in a stack or wound into a roll for dispensing.
  • In one embodiment of the present invention, one or more botanical compounds are introduced into or onto a fibrous wipe substrate, absorbent substrate, a solution or ointment for use with a wipe substrate or absorbent article. When the wipe or absorbent article contacts skin or mucosa, the botanical compound contacts the skin or mucosa, and may be actually transferred to the skin or mucosa, thereby selectively affecting the growth and/or adherence of flora to the portion of the skin or mucosa contacted by the wipe or absorbent article. In a specific embodiment, the botanical compound is introduced into the liquid formulation of a wet wipe. The botanical compound preferably promotes the adherence of at least one healthy flora to the surface of skin or mucosa, and/or inhibits the growth of at least one problem flora on or around the skin surface, and/or inhibits the adherence of at least one problem flora to the surface of skin or mucosa.
  • As noted above, beneficial flora are often naturally found on the skin or mucosal surfaces of the body, and may provide a variety of beneficial effects. It is thus often desirable to maintain or promote the adherence of such healthy flora to the surface of skin or mucosa to increase the benefit. Some examples of healthy flora include Lactobacillus acidophilus, some other Lactobacillus species, and Atopobium species, and to an extent, Staphlococcus epidermidis.
  • Unlike healthy flora, problem flora, such as pathogenic bacteria or yeast, as noted above, are associated with numerous ailments, including skin infections, diaper rash, urinary or vaginal infections, and malodors, among others. As such, it is often desirable to selectively inhibit the growth and/or adherence of these problem flora. Some examples of problem flora include Candida albicans, Proteus mirabilis, and Pseudomonas aeruginosa. It will be apparent to those skilled in the art that there are numerous other examples of both healthy and problem flora, other than those described herein, and that the growth and/or adherence of these flora may be controlled in a manner similar to that described herein.
  • Suitable botanical compounds for use in combination with the personal care products described herein include botanical compounds that have one or more of the following effects when contacted with the skin: (i) promote the adherence of Lactobacillus acidophilus to the surface of skin or mucosa; (ii) promote the adherence of Staphlococcus epidermidis to the surface of skin; (iii) inhibit the growth on or around the skin surface of at least one organism selected from the group consisting of Candida albicans, Proteus mirabilis, Pseudomonas aeruginosa, and Staphlococcus epidermidis; and (iv) inhibit the adherence to the surface of skin or mucosa of at least one organism selected from the group consisting of Candida albicans, Proteus mirabilis, Pseudomonas aeruginosa, and Staphlococcus epidermidis.
  • The protocols for testing the ability of botanical compounds to elicit any of these desired effects are set forth in the Examples. In general, the ability of a botanical compound to affect the adherence of an organism to skin is determined by comparing the adherence of the organism to skin in the presence of the botanical compound, to the adherence of the organism to skin in the absence of the botanical compound. If the amount of adherence in the presence of the botanical compound is 150% or greater than the amount of adherence in the absence of the botanical compound, then the botanical compound is an adherence promoter for that organism. If the amount of adherence in the presence of the botanical compound is 50% or less than the amount of adherence in the absence of the botanical compound, then the botanical compound is an anti-adherent for that organism.
  • Similarly, the ability of a compound to inhibit the growth of an organism (Examples 1 and 2) is determined relative to a control. As the following equations indicate, optical density of a sample containing a botanical compound and an organism and a control containing only the organism are measured at 0 and 18 hours:
    [(OD 650 sample @18 hours—OD 650 sample @0 hours)/(OD 650 yeast only @18 hours—OD 650 yeast only @0 hours)]*100;
    [(OD 650 sample @18 hours—OD 650 sample @0 hours)/(OD 650 bacteria only @18 hours—OD 650 bacteria only @0 hours)]*100.
  • For purposes of the present invention, a botanical compound is considered a growth inhibitor if the botanical compound has an IC50 value of 5% or less for the organism being tested, wherein IC50 is the concentration that inhibits the growth of the organism by 50%.
  • A variety of botanical compounds were tested using the protocols described herein with the results set forth in Tables 1 and 2. However, the ability of numerous other botanical compounds to affect the growth and/or adherence of healthy and/or problem flora to the surface of skin or mucosa, in addition to those tested herein, may also be determined using these protocols.
  • Some botanical compounds may have multiple beneficial effects. In addition, some botanical compounds may have one or more beneficial effect, as described above, as well as a less desired effect, such as inhibiting the adherence of Lactobacillus acidophilus to the surface of skin or mucosa. Such compounds may still be useful in combination with a wipe or absorbent article, of the present invention, depending on the type of wipe or absorbent article and the intended use of such product.
  • In one specific embodiment, a botanical compound which does not substantially promote the adherence of C. albicans, P. mirabilis, and P. aeruginosa is introduced into a solution for use in combination with a wipe substrate or absorbent article. In this embodiment, the botanical compound may increase the adherence of L. acidophilus or S. epidermidis, or may inhibit the growth and/or adherence to the surface of skin or mucosa of S. epidermidis, C. albicans, P. mirabilis, or P. aeruginosa. Suitable botanical compounds include Aloe Ferox HS, American Ginseng, Arkin Special, Bleuet MCF 783 Hydro, Calendula (Marigold), Ceramide Complex, Comfey leaves, Cromoist 0-25, Cromoist HYA, Dandelion, Devil's Claw, Dong Quai, Drago-Oat Active, Echinacea Dry Aq., Gingko Biloba, Ginseng GR 471 Hydro, Glucosamine 99, Goldenseal, Gotu Kola PG 5:1, Grape Seed, Grape Seed Extr., Green Tea, Green Tea Conc., Green Tea Extr., Green Tea HS, Hydrocotyle GR 040, Hydrolactin 2500, Hydrolite-5, Hydrosoy 2000 SF, Lamier Blanc MCF 796, Lavendar MCF 1484, Lime Blossom, Lime Blossom Distillate, Marigold (Calendula), Marron d'inde (horse chestnut), Marron d'inde MCF 1972, Milk Thistle, Nab Willowbark Extr., NSLE Lipomicron, Pineapple B, Sage Special, Sandal Complex, Soluble Wheat Protein, Spirulina, St. John's Wort W/S, White Mistle Toe, Witchhazel distillate, Witchhazel GW, Yucca 70, and. Yucca Extr. Powder 50%.
  • As previously discussed, L. acidophilus is a beneficial organism. As such, it is desirable to promote the adherence of L. acidophilus to the surface of skin or mucosa. Thus, in one embodiment, a botanical compound that is capable of increasing the adherence of L. acidophilus to the surface of skin or mucosa by at least about 50%, is incorportaed into or onto a product of the present invention. Suitable botanical compounds include Aloe Ferox HS, American Ginseng, Calendula (Marigold), Ceramide Complex, Comfey Leaves, Cromoist 0-25, Cromoist HYA, Dandelion, Devil's Claw, Dong Quai, Drago-Oat Active, Echinacea Dry Aq., Gingko Biloba, Ginseng GR 471 Hydro, Glucosamine 99, Goldenseal, Gotu Kola PG 5:1, Grape Seed, Green Tea, Hydrolite-5, Hydrosoy 2000 SF, Marron D'Inde (Horse Chestnut), Milk Thistle, Nab Willowbark Extr., Soluble Wheat Protein, Spirulina, St. John's Wort W/S, White Mistle Toe, Witchhazel Distillate, Witchhazel GW, Yucca 70, and Yucca Extr. Powder 50%. More specifically, the botanical compound is capable of increasing the adherence of L. acidophilus to the surface of skin or mucosa by at least about 1000%. Suitable botanical compounds include Calendula (Marigold), Ceramide Complex, Echinacea Dry Aq., Grape Seed, Spirulina, Witchhazel GW, and Yucca 70. Additionally, a suitable botanical compound that is capable of increasing the adherence of L. acidophilus to the surface of skin or mucosa is selected from the group consisting of Aloe Ferox HS, American Ginseng, Calendula (Marigold), Ceramide Complex, Comfey Leaves, Cromoist 0-25, Cromoist HYA, Dandelion, Devil's Claw, Dong Quai, Drago-Oat Active, Ginseng GR 471 Hydro, Glucosamine 99, Gotu Kola PG 5:1, Grape Seed, Hydrolite-5, Hydrosoy 2000 SF, Marron D'Inde (Horse Chestnut), Milk Thistle, Soluble Wheat Protein, Spirulina, Witchhazel Distillate, and Witchhazel GW.
  • The product comprising the botanical compound that promotes the adherence of L. acidophilius to the skin can be a feminine wipe, feminine napkin, tampon, or interlabial pad. A feminine wipe is a hygenic wipe that may be used to clean blood, menses and/or other body exudates from the skin and hair in the pudendal region of the body. As previously discussed, L. acidophilius colonizes the vaginal epithelium during child-bearing years, and inhibits the growth of some pathogens in the vaginal region. It would thus be particularly beneficial to introduce into or onto a feminine product one or more botanical compounds that promote the adherence of L. acidophilius to the surface of skin or mucosa. In contrast, botanical compounds such as Grape Seed Extract, Green Tea Conc., Lavendar MCF 1484, Lime Blossom, Lime Blossom Distillate, and Pineapple B inhibit the adherence of L. acidophilius to the surface of skin or mucosa, and would thus not be particularly beneficial for a feminine product, but may be suitable for use in combination with other types of wipes or absorbent articles, as described herein.
  • As previously indicated, in some instances it may be beneficial to promote the adherence of S. epidermidis to the surface of skin. Thus, a botanical compound that is capable of promoting the adherence of S. epidermidis to the surface of skin by at least about 50% can be used in combination with a product of the present invention. Suitable botanical compounds include Bleuet MCF 783 Hydro, Hydrocotyle GR 040, Hydrolactin 2500, Lavendar MCF 1484, Lime Blossom, Lime Blossom Distillate, Marigold (Calendula), and Sage Special.
  • As previously discussed, L. acidophilius is a beneficial flora, and, as such, it is advantageous not to inhibit the growth or adherence of L. acidophilius to the surface of skin or mucosa. Thus, in an even more specific embodiment of the above, the botanical compound is capable of increasing the adherence of S. epidermidis to the surface of skin by at least about 50%, and does not inhibit the growth of L. acidophilius on or around the skin surface, nor does it significantly inhibit the adherence of L. acidophilius to the surface of skin or mucosa. Such suitable botanical compounds include Bleuet MCF 783 Hydro, Hydrocotyle GR 040, Hydrolactin 2500, Marigold (Calendula), and Sage Special.
  • In addition to promoting the adherence of healthy flora, it may be beneficial to inhibit the adherence of problem flora to the surface of skin or mucosa. The products of the present invention may thus incorporate a botanical compound that inhibits the adherence of C. albicans, P. mirabilis, or P. aeruginosa to the surface of skin or mucosa. Thus, in one embodiment, the botanical compound is capable of inhibiting the adherence of C. albicans to the surface of skin or mucosa by at least about 50%. Suitable botanical compounds include Aloe Ferox HS, American Ginseng, Arkin Special, Comfey Leaves, Dong Quai, Echinacea Dry Aq., Glucosamine 99, Goldenseal, Grape Seed, Grape Seed Extr., Green Tea, Green Tea Conc., Green Tea Extr., Green Tea HS, Hydrolite-5, Lavendar MCF 1484, Marron D'Inde MCF 1972, Marron D'Inde (Horse Chestnut), Pineapple B, Sandal Complex, Soluble Wheat Protein, Yucca 70, and Yucca Extr. Powder 50%. More specifically, the botanical compound is capable of inhibiting the adherence of C. albicans to the surface of skin or mucosa by at least about 70%. Suitable botanical compounds include Aloe Ferox HS, Comfey Leaves, Glucosamine 99, Grape Seed, Green Tea, Green Tea Extr., Hydrolite-5, Pineapple B, Sandal Complex, Yucca 70, and Yucca Extr. Powder 50%. The botanical compound capable of inhibiting the adherence of C. albicans may also be selected from the group consisting of Aloe Ferox HS, American Ginseng, Comfey Leaves, Dong Quai, Glucosamine 99, Grape Seed, Green Tea Conc., Hydrolite-5, Lavendar MCF 1484, Marron D'Inde MCF 1972, Marron D'Inde (Horse Chestnut), Pineapple B, Sandal Complex, and Soluble Wheat Protein.
  • In another specific embodiment, the botanical compound is capable of inhibiting the adherence of P. mirabilis to the surface of skin or mucosa by at least about 50%. Suitable botanical compounds include Aloe Ferox HS, Cromoist HYA, Echinacea Dry Aq., Gingko Biloba, Grape Seed Extr., Green Tea, Green Tea Extr., Green Tea HS, Hydrolactin 2500, Hydrolite-5, Hydrosoy 2000 SF, Marron D'Inde (Horse Chestnut), Marron D'Inde MCF 1972, NSLE Lipomicron, Pineapple B, Sandal Complex, Witchhazel GW, Yucca 70, and Yucca Exr. Powder 50%. More specifically, the botanical compound is capable of inhibiting the adherence of P. mirabilis to the surface of skin or mucosa by at least about 70%. Suitable botanical compounds include Aloe Ferox HS, Echinacea Dry Aq., Gingko Biloba, Grape Seed Extr., Green Tea, Green Tea Extr., Hydrolactin 2500, Hydrolite-5, Marron D'Inde (Horse Chestnut), NSLE Lipomicron, Pineapple B, Sandal Complex, Witchhazel GW, Yucca 70, and Yucca Extr. Powder 50%. Even more specifically, the botanical compound capable of inhibiting the adherence of P. mirabilis is selected from the group consisting of Aloe Ferox HS, Hydrolactin 2500, Hydrolite-5, Marron D'Inde (Horse Chestnut), Pineapple B, Sandal Complex, and Witchhazel GW.
  • In another specific embodiment, the botanical compound is capable of inhibiting the adherence of Pseudomonas aeruginosa to the surface of skin or mucosa by at least about 50%. Suitable botanical compounds include Ceramide Complex, Echinacea Dry Aq., Grape Seed Extr., Green Tea, Green Tea Extr., Hydrolite-5, Nab Willowbark Extr., NSLE Lipomicron, Pineapple B, Sandal Complex, Soluble Wheat Protein, Yucca 70, and Yucca Extr. Powder 50%. More specifically, the botanical compound capable of inhibiting the adherence of Pseudomonas aeruginosa is selected from the group consisting of Ceramide Complex, Hydrolite-5, NSLE Lipomicron, Pineapple B, Sandal Complex, and Soluble Wheat Protein.
  • Since, as previously discussed, S. epidermidis can become an opportunistic pathogen, especially when exposed to breaks in the skin barrier, it would be advantageous to inhibit the adherence of S. epidermidis to the surface of skin, or to inhibit the growth of S. epidermidis on or around the skin surface when treating wounds. Thus, it would be particularly beneficial to introduce into or onto a wipe used for wound care or other wound management products a botanical compound that inhibits the adherence of Staphlococcus epidermidis to the surface of skin and/or inhibits the growth of S. epidermidis on or around the skin surface.
  • The products of the present invention may thus incorporate a botanical compound that inhibits the adherence of S. epidermidis to the surface of skin. In one embodiment, the botanical compound is capable of inhibiting the adherence of Staphlococcus epidermidis to the surface of skin by at least about 50%. Suitable botanical compounds include Aloe Ferox HS, Arkin Special, Comfey Leaves, Cromoist HYA, Devil's Claw, Echinacea Dry Aq., Gingko Biloba, Goldenseal, Gotu Kola PG 5:1, Grape Seed Extr., Green Tea, Hydrosoy 2000 SF, Marron D'Inde (Horse Chestnut), Marron D'Inde MCF 1972, Pineapple B, Soluble Wheat Protein, St. John's Wort W/S, White Mistle Toe, and Yucca 70. More specifically, the botanical compound that is capable of inhibiting the adherence of Staphlococcus epidermidis is selected from the group consisting of Aloe Ferox HS, Comfey Leaves, Cromoist HYA, Devil's Claw, Gotu Kola PG 5:1, Hydrosoy 2000 SF, Marron D'Inde (Horse Chestnut), Marron D'Inde MCF 1972, Pineapple B, and Soluble Wheat Protein.
  • In another embodiment, the botanical compound is capable of inhibiting the growth of Staphlococcus epidermidis on or around the skin surface. Suitable botanical compounds include compounds that have an IC50 value of about 5% or less for S. epidermidis, including Aloe, Ferox HS, Goldenseal, Grape Seed Extr., Green Tea, and Pineapple B. More specifically, the botanical compound that is capable of inhibiting the growth of Staphlococcus epidermidis is selected from the group consisting of Aloe Ferox HS and Pineapple B.
  • As previously discussed, it may be beneficial to inhibit the growth of other problem flora on or around the skin surface. The products of the present invention may thus incorporate a botanical compound that inhibits the growth of C. albicans, P. mirabilis, or P. aeruginosa on or around the skin surface. Thus, in one specific embodiment, the botanical compound is capable of inhibiting the growth of Candida albicans on or around the skin surface. Suitable botanical compounds include compounds that have an IC50 value of about 5% or less for C. albicans, and include Echinacea Dry Aq., Glucosamine 99, Goldenseal, Grape Seed Extr., Green Tea, Green Tea Conc., and Green Tea Extr. More specifically, the botanical compound that is capable of inhibiting the growth of Candida albicans is selected from the group consisting of of Glucosamine 99 and Green Tea Conc.
  • In another specific embodiment, the botanical compound is capable of inhibiting the growth of Proteus mirabilis on or around the skin surface. Suitable botanical compounds include compounds that have an IC50 value of about 5% or less for Proteus mirabilis, including Gingko Biloba, Grape Seed Extr., Hydrolite-5, and Yucca 70. More specifically, the botanical compound that is capable of inhibiting the growth of Proteus mirabilis is Hydrolite-5.
  • In yet another specific embodiment, the botanical compound is capable of inhibiting the growth of Pseudomonas aeruginosa on or around the skin surface. Suitable botanical compounds include compounds that have an IC50 value of about 5% or less for Pseudomonas aeruginosa, including Grape Seed Extr., Green Tea Extr., and Hydrolite-5. More specifically, the botanical compound that is capable of inhibiting the growth of Pseudomonas aeruginosa is Hydrolite-5.
  • The products of the present invention may also incorporate a botanical compound that is capable of inhibiting the growth of at least one problem flora on or around the skin surface, the problem flora selected from the group consisting of Candida albicans, Proteus mirabilis, and Pseudomonas aeruginosa. Suitable botanical compounds are selected from the group consisting of Green Tea Extr., Hydrolite-5, Sandal Complex, and Yucca Extr. Powder 50%, and more specifically, from the group consisting of Hydrolite-5 and Sandal Complex.
  • The products of the present invention may also comprise a combination of two or more of the botanical compounds described herein in order to provide multiple benefits to the end user. Numerous combinations of botanical compounds may be introduced onto a wipe substrate, absorbent substrate, or into a wet wipe solution for use in combination with a wipe substrate, wherein each botanical compound provides at least one different effect than any other compound. For example, one beneficial combination would be to promote the adherence of Lactobacillus acidophilus, while at the same time inhibiting the adherence of at least one problem organism. Thus, in one embodiment, a product of the present invention incorporates a first botanical compound that promotes the adherence of Lactobacillus acidophilus to the surface of skin or mucosa by at least about 50% in combination with a second botanical compound that inhibits the adherence of at least one organism to the surface of skin or mucosa, the organism selected from the group consisting of Candida albicans, Proteus mirabilis, Pseudomonas aeruginosa, and Staphylococcus epidermidis. In this embodiment, the second botanical compound is capable of inhibiting the adherence of the organism to the surface of skin or mucosa by at least about 50%.
  • In addition to promoting the adherence of Lactobacillus acidophilus and inhibiting the adherence of at least one problem organism, it may also be beneficial to inhibit the growth of one or more problem organism such as C. albicans, P. mirabilis, P. aeruginosa, and/or S. epidermidis. Thus, these products may additionally incorporate a third botanical that inhibits the growth of C. albicans, P. mirabilis, P. aeruginosa, and/or S. epidermidis on or around the skin surface. In one embodiment, the third botanical has an IC50 value of about 5% or less for C. albicans. In another embodiment, the third botanical has an IC50 value of about 5% or less for P. mirabilis. In yet another embodiment the third botanical has an IC50 value of about 5% or less for P. aeruginosa. In still another embodiment, the third botanical has an IC50 value of about 5% or less for S. epidermidis.
  • Another beneficial combination would be to promote the adherence of Lactobacillus acidophilus, while at the same time promoting the adherence of Staphylococcus epidermidis. Thus, in one embodiment, the products of the invention incorporate a first botanical compound that promotes the adherence of Lactobacillus acidophilus to the surface of skin or mucosa by at least about 50% in combination with a second botanical compound that promotes the adherence of Staphylococcus epidermidis to the surface of skin by at least about 50%.
  • In addition to promoting the adherence of Lactobacillus acidophilus and Staphylococcus epidermidis, it may also be beneficial to inhibit the adherence of at least one problem organism, such as C. albicans, P. mirabilis, and/or P. aeruginosa. Thus, the product may further incorporate a third botanical compound that inhibits the adherence of at least one organism to the surface of skin or mucosa, the organism selected from the group consisting of Candida albicans, Proteus mirabilis, and Pseudomonas aeruginosa, wherein the third botanical compound is capable of inhibiting the adherence of the organism to the surface of skin or mucosa by at least about 50%.
  • Such a combination may be further enhanced by incorproating into a product a fourth botanical compound that inhibits the growth of at least one problem organism, such as Candida albicans, Proteus mirabilis, and/or Pseudomonas aeruginosa. Thus, in one embodiment, the fourth botanical compound inhibits the growth of Candida albicans on or around the skin surface, the fourth botanical compound having an IC50 value of about 5% or less for Candida albicans. In another specific embodiment, the fourth botanical compound inhibits the growth of Proteus mirabilis on or around the skin surface, the fourth botanical compound having an IC50 value of about 5% or less for Proteus mirabilis. In yet another specific embodiment, the fourth botanical compound inhibits the growth of Pseudomonas aeruginosa on or around the skin surface, the fourth botanical compound having an IC50 value of about 5% or less for Pseudomonas aeruginosa.
  • Another beneficial combination would be to inhibit the adherence of at least one problem organism, such as Candida albicans, Proteus mirabilis, Pseudomonas aeruginosa, and/or Staphylococcus epidermidis, while at the same time inhibiting the growth of at least one problem organism, such as Candida albicans, Proteus mirabilis, Pseudomonas aeruginosa, and/or Staphylococcus epidermidis. Thus, in one embodiment, the products of the invention incorporate a first botanical compound that inhibits the adherence of at least one organism selected from the group consisting of Candida albicans, Proteus mirabilis, Pseudomonas aeruginosa, and/or Staphylococcus epidermidis, to the surface of skin or mucosa in combination with a second botanical compound that inhibits the growth of at least one organism selected from the group consisting of Candida albicans, Proteus mirabilis, Pseudomonas aeruginosa, and Staphylococcus epidermidis, on or around the skin surface. The first botanical compound is capable of inhibiting the adherence of the organism to the surface of skin or mucosa by at least about 50%, and the second botanical compound has an IC50 value of about 5% or less for Candida albicans, Proteus mirabilis, Pseudomonas aeruginosa, and/or Staphylococcus epidermidis.
  • The present invention is also directed to a wipe for use in wound care. The wipe comprises (a) a fibrous wipe substrate; (b) a first botanical compound that inhibits the adherence of Staphylococcus epidermidis to the surface of skin by at least about 50%; and (c) a second botanical compound that inhibits the growth of Staphylococcus epidermidis on or around the skin surface, the second botanical compound having an IC50 value of about 5% or less for Staphylococcus epidermidis.
  • In another specific embodiment, the present invention is directed to a wet wipe for promoting the adherence of Lactobacillus acidophilus to the surface of skin or mucosa. The wipe comprises a fibrous wipe substrate, a liquid formulation, and a botanical compound capable of increasing the adherence of Lactobacillus acidophilus to the surface of skin or mucosa by at least about 50%, wherein the liquid formulation is selected from the group consisting of a solution, a suspension, and an emulsion.
  • In addition to wipes and absorbent articles, the present invention is also directed to a method for selectively controlling the balance of flora on the skin. The method includes contacting a fibrous wipe substrate or absorbent substrate with the skin surface. The substrate includes a botanical compound for selectively controlling the growth and/or adherence of flora to the skin, wherein the compound promotes the adherence of at least one healthy flora to the surface of skin or mucosa, inhibits the growth of at least one problem flora on or around the skin surface, or inhibits the adherence of at least one problem flora to the surface of skin or mucosa, or any combination thereof. Additionally, a suitable method includes contacting a fibrous wipe substrate or absorbent substrate with the skin surface, wherein the substrate includes two or more botanical compounds for selectively controlling the growth and/or attachment of flora to the skin, wherein each compound promotes the adherence of at least one healthy flora to the surface of skin or mucosa, inhibits the growth of at least one problem flora on or around skin surface, or inhibits the adherence of at least one problem flora to the surface of skin or mucosa, or any combination thereof.
  • A more specific method involves promoting the adherence of Lactobacillus acidophilus to the surface of skin or mucosa. This method includes contacting a fibrous wipe substrate or absorbent substrate with the surface of skin or mucosa, wherein the substrate includes a botanical compound that is capable of increasing the adherence of Lactobacillus acidophilus to the surface of skin or mucosa by at least about 50%.
  • When present on a dry substrate, the botanical compound that selectively controls the balance of flora on skin is present in an amount of from about 0.01% (by weight of the treated substrate or product) to about 50% (by weight of the treated substrate or product), preferably from about 0.01% (by weight of the treated substrate or product) to about 10% (by weight of the treated substrate or product). When present as part of the liquid formulation used in combination with a wet wipe or absorbent article, the botanical compound is present in an amount of from about 0.01% (by total weight of the liquid formulation) to about 50% (by total weight of the liquid formulation), more preferably from about 0.01% (by total weight of the liquid formulation) to about 10% (by total weight of the liquid formulation).
  • Liquid formulations comprising botanical compounds, described herein, suitable for use in combination with a wipe or absorbent substrate can be solutions, suspensions, or emulsions. Many of the botanical compounds are substantially water-soluble or can be easily solubilized in water using techniques known to one skilled in the art to provide solutions comprising the botanical compound. Some botanical compounds described herein which are not substantially water-soluble or easily solubilized can be suspended or emulsified utilizing techniques known to one skilled in the art. Suitable emulsions include oil-in-water emulsions which can be prepared using suitable emulsifiers having an HLB greater than about 7 or can be water-in-oil emulsions prepared using suitable emulsifiers having an HLB of less than about 7. In order to sufficiently protect the water-soluble and/or hydrophilic compounds from premature oxidation during processing and/or product shelf storage, water-in-oil emulsions are typically particularly useful. The emulsified layer around the water phase can prevent oxygen from entering the water phase.
  • Alternatively or additionally, the botanical compounds can be encapsulated to prevent premature oxidation during process and product storage. Many encapsulation techniques known in the art can be utilized including those which provide sustained release, triggered release, targeted release or a combination of these release mechanisms. Other release mechanisms known in the art and suitable for use in accordance with the present invention include friction/pressure release, pH related release, water release, water evaporation release, and the like. Encapsulated botanical compounds can be delivered from both wet and dry wipe products. Suitable microencapsulation materials suitable for use in combination with the botanical compounds described herein include those available from Salvona, LLC (Dayton, N.J.).
  • Additionally, liposomes and/or nanosomes can be utilized to deliver and protect the botanical compounds described herein from premature oxidation in both a wet and a dry wipe product. As used herein, the terms liposomes and nanosomes are meant to include closed vesicles with walls composed of lipid-bilayer membranes to protect and deliver the core compound material.
  • Another method for delivering botanical compounds from a wet or dry wipe product or absorbent article and protecting these components from premature oxidation includes utilizing polymeric entrapment systems such as microspheres, microsponges, and polytraps such as those available from Advance Polymer Systems (Redwood City, Calif.). The botanical compound can be entrapped or adsorbed into the interstitial spaces of a polymer matrix thereby protecting the botanical compound from degredation and/or premature oxidation.
  • Particularly useful for delivering the botanical compound from dry substrates are semi-solid or solid formulations which transfer to the skin during use by the consumer. These formulations can be hydrophobic or hydrophilic in nature. The hydrophobic formulations are semi-solid or solid in nature at room temperature with a melting point greater than about 35° C. and contain from about 5 to about 95 weight percent of an emollient, from about 5 to about 95 weight percent of a solidifying agent such as an alpha olefin polymer, polyethylene, oxidized polyethylene, fatty alcohol, wax, or solid esters with a melting point of 35° C. or greater, from about 1 to about 50 weight percent of a viscosity enhancer such as silica, ethylene vinyl acetate copolymers, or an organo-clay and from about 0.1 to about 15 weight percent of an antioxidant agent.
  • The hydrophilic formulations are semi-solid or solid at room temperature with a melting point greater than about 35° C. and contain from about 30 to about 90 weight percent of a hydrophilic solvent/emollient such as water, propylene glycol, butylene glycol, low molecular weight (less than about 720) polyethylene glycols, dipropylene glycol glycerin, silicone glycols, methyl propanediol, or pentylene glycol, from about 10 to about 50 weight percent high molecular weight (greater than about 750) polyethylene glycol, from about 5 to about 40 weight percent of a fatty alcohol having from about 14 to about 30 carbons in the chain, optionally from about 1 to about 15 weight percent of a viscosity enhancer such as clays, glyceryl polyacrylates, or glyceryl polymethacrylates and from about 0.1 to about 15 weight percent of an antioxidant agent.
  • The dry wipe formulations can also be readily emulsifiable solid formulations with a melting point greater than about 35° C. and contain from about 5 to about 95 weight percent of a hydrophobic or hydrophilic emollient as set forth above, from about 5 to about 95 weight percent of a suitable solidifying agent as set forth above, from about 5 to about 25 weight percent of a suitable emulsifier and from about 1 to about 15 weight percent of an antioxidant agent. The suitable emulsifier can be anionic, cationic, amphoteric, zwitterionic, or nonioinic and combinations thereof.
  • In order to enhance consumer appeal, additional ingredients can be added to the above-described formulations. Suitable additional ingredients include, for example, anti-acne actives, antifoaming agents, antimicrobial actives, antifungal actives, antiseptic actives, antioxidants which prevent oxidation during processing and storage by preferentially oxidizing, astringents, colorants, deodorants, film formers, fragrances, moisturizers, skin protectants, sunscreen actives, and solvents.
  • The present invention is illustrated by the following examples which are merely for the purpose of illustration and are not to be regarded as limiting the scope of the invention or manner in which it may be practiced.
  • EXAMPLES
  • Various botanical compounds were tested to determine whether the botanical compound inhibited or enhanced bacterial or yeast attachment to the skin. Tests were also performed to determine if any of these botanical compounds exhibited antimicrobial activity. The botanical compounds and the combined results of these tests are set forth in Tables 1 and 2. Descriptions of the protocols for performing these tests are set forth in the following examples.
  • Example 1 Bacteria Kill Assay
  • The ability of various botanical compounds to inhibit the growth of P. mirabilis, P. aeruginosa, and S. epidermidis, was tested. This protocol can also be applied to test the ability of botanical compounds to inhibit the growth of other bacteria, in addition to those tested herein.
  • To begin, a 10% solution of each botanical in trypticase soy broth (TSB) was prepared by adding either 1 ml or 1 g of botanical to 9 or 10 ml TSB, respectively. Two-fold dilutions of the botanical solutions were performed in a 96 well plate. The dilutions were performed as follows:
      • 10%: 100 ul of the 10% stock is added to the well
      • 5%: 50 ul from the 10% well plus 50 ul TSB
      • 2.5%: 50 ul from the 5% well plus 50 ul TSB
      • 1.25%: 50 ul from the 2.5% well plus 50 ul TSB
      • 0.625%: 50 ul from the 1.25% well plus 50 ul TSB
      • 0.3125%: 50 ul from the 0.625% well plus 50 ul TSB
  • The final volume in each well was 50 ul after discarding 50 ul from the 0.3125% dilution. All experiments were done in triplicate.
  • P. mirabilis (ATCC #29906), P. aeruginosa (ATCC #27853), or S. epidermidis (ATCC #12228) were cultured overnight. The overnight culture was diluted with TSB to a concentration of about 1×106 cells/ml. 50 μl of this diluted bacterial culture was added to each well containing the diluted botanical solutions, to form sample solutions comprising diluted bacterial cultures at the concentrations described above and the diluted botanical solution. 50 μl of this diluted bacterial culture was also added to 50 μl TSB and used as a negative control. The optical density (650 nm) of the control and the samples was determined using a spectrophotometer. Both the control and the sample were then incubated for 16 to 18 hours at 37° C., with agitation at about 400 rpm. The wells were again inserted into the spectrophotometer, and further shaken. The optical density (650 nm) of the control and the sample was read again. The percentage of bacterial growth in the sample relative to the control was determined by the following equation:
    [(OD 650 sample @18 hours—OD 650 sample @0 hours)/(OD 650 bacteria only @18 hours—OD 650 bacteria only @0 hours)]*100
  • The results for the three wells comprising each dilution step were averaged. The results were plotted, and an IC50 value for each botanical compound was determined.
  • The results are given in Table 2, which shows the effect of various botanical compounds on the growth of C. albicans, P. aeruginosa, P. mirablis, and S. epidermidis relative to a negative control (compounds not tested are marked with a dash). The lower the IC50 value, the more potent a growth inhibitor the botanical compound was. An IC50 value of greater than 10% indicates that no growth inhibition was observed. Botanical compounds with an IC50 value of 10% or less showed some ability to inhibit growth. However, for purposes of the present invention, botanical compounds that have an IC50 value of about 5% or less are considered growth inhibitors.
  • Example 2 Yeast Kill Assay
  • The ability of various botanical compounds to inhibit the growth of C. albicans was tested. The protocol described herein can also be applied to test the ability of botanical compounds to inhibit the growth of other yeast, in addition to C. albicans.
  • To begin, a 10% solution of each botanical in TSB was prepared by adding either 1 ml or 1 g of botanical to 9 or 10 ml TSB, respectively. Dilutions were performed, as described in Example 1.
  • C. albicans (ATCC #10231) was cultured overnight. The overnight culture was diluted with TSB to a concentration of about 1×106 cells/ml. 50 μl of this diluted yeast culture was added to each well containing the diluted botanical solutions, to form sample solutions comprising diluted yeast cultures at the concentrations described above and the diluted botanical solution. 50 μl of this diluted yeast culture was also added to 50 μl TSB and used as a negative control. The optical density (650 nm) of the control and the samples was determined using a spectrophotometer. Both the control and the sample were then incubated for 16 to 18 hours at 37° C., with agitation at about 400 rpm. The wells were again inserted into the spectrophotometer, and further shaken. The optical density (650 nm) of the control and the sample was read again. The percentage of yeast growth in the sample relative to the control was determined by the following equation:
    [(OD 650 sample @18 hours—OD 650 sample @0 hours)/(OD 650 yeast only @18 hours—OD 650 yeast only @0 hours)]*100
  • The results for the three wells comprising each dilution step were averaged. The results were plotted, and an IC50 value for each botanical compound was determined. The results are given in Table 2, as described in Example 1.
  • Example 3 Adhesion Assay for P. mirabilis, S. epidermidis, and P. aeruginosa
  • Each of the botanical compounds listed in Table 1 was screened to measure the effect of the compound on the adhesion of P. mirabilis, S. epidermidis, or P. aeruginosa to the skin. The protocol described herein can also be applied to test the effect of botanical compounds on the adhesion of other bacteria to the skin.
  • Two days prior to the screen, a bacterial culture of either P. mirabilis (ATCC #29906), S. epidermidis (ATCC #12228), or P. aeruginosa (ATCC #27853) was prepared. One frozen bead of bacteria was added to 10 ml of TSB, and grown overnight at 37° C. with agitation at 100 rpm. A synthetic skin substrate (VITRO-SKIN® substrate) was placed in a hydration chamber overnight.
  • One day prior to the screen, discs of the synthetic skin, sized to fit the wells of a 96 well plate, were cut out in a controlled humidity room using a #2 tool. The discs were placed in the wells of the plate, and the plate was stored in a humidity chamber. A TSB culture was prepared by inoculating TSB with the overnight culture, previously described, at a ratio of 1:1000 (overnight culture:TSB). The TSB culture was then grown overnight at 37° C. with agitation at 100 rpm. A 10% solution of each botanical in TSB was prepared by adding either 100 μl of botanical to 900 μl TSB, or if the botanical was a solid, using 100 mg of botanical and a sufficient amount of TSB to bring the total volume to 1 ml. 10% Tween® 20 stock in TSB was prepared as a positive control by adding 100 μl of Tween® 20 to the appropriate amount of TSB, to give a 10% solution.
  • The next day, the optical density (650 nm) of the TSB culture was read. It was assumed that 1 OD was equal to 1×108 cells/ml. The culture was centrifuged at 5,000×g for 10 minutes to pellet the bacteria. The bacteria were resuspended in a sufficient amount of TSB, so that the final concentration of bacteria was 1×106 cells/ml. 50 μl of either the 10% botanical stock or the control solution was added to wells containing the synthetic skin substrate. 50 μl of the bacteria in TSB was then added to each of these wells, and the cells were allowed to adhere to the synthetic skin for three hours at room temperature, shaking slowly. After three hours, the solutions were removed from the wells, and the synthetic skin was washed three times with a solution of 250 μl of phosphate buffered saline (PBS) plus 0.05% Tween® 20. The skin was transferred to a white plate, and 200 μl of 10% AlamarBlue® dye in TSB was added to each well. The plate was incubated at 37° C. AlamarBlue® levels were read (emission levels read at 590 nm) in an Ascent plate reader (excitation level of 544 nm) at 1 and 2 hours. When not being read, the plate was incubated at 37° C. with a lid.
  • Results are given in Table 1, which gives the percent adherence to the skin of P. mirabilis, S. epidermidis, P. aeruginosa, L. acidophilus, and C. albicans for the various botanical compound samples, relative to the control. The percentage is based on the number of cells that adhered to the skin for the botanical samples as compared to the number of cells that adhered to the skin in the control, as determined by the AlamarBlue® levels. A percentage greater than 100% indicated that more cells adhered with the botanical sample than with the control; a percentage less than 100% indicated that fewer cells adhered with the botanical sample than with the control. For purposes of the present invention, if the percentage is 150% or greater, the botanical compound is considered to be an adherence promoter for the particular organism; if the percentage is 50% or lower, the botanical compound is considered to be an anti-adherent for the particular organism.
  • Some of the compounds in Table 2 that are listed as growth inhibitors for certain organisms have a percent adherence of less than 50% for that organism. In this situation, no conclusion can be drawn as to the anti-adherent properties of the botanical compound, as it is unclear whether the low percent adherence is due to anti-adherent properties of the botanical compound, or to the compound's growth inhibiting properties.
  • Example 4 Adhesion Assay for Lactobacillus acidophilus
  • Each of the compounds listed in Table 1 was screened to measure the effect of the compound on the adhesion of Lactobacillus acidophilus to the skin.
  • Two days prior to the screen, a bacterial culture of Lactobacillus acidophilus was prepared. One frozen bead of Lactobacillus acidophilus (ATCC #:314) was added to 10 mL of Lactobacilli broth, and the culture was incubated overnight at 37° C. A synthetic skin substrate (VITRO-SKIN® substrate) was placed in a hydration chamber overnight.
  • One day prior to the screen, discs of the synthetic skin, sized to fit the wells of a 96 well plate, were cut out using a #2 tool. The discs were placed in the wells of the plate, and the plate was stored in a humidity chamber. A Lactobacilli broth culture was prepared by inoculating Lactobacilli broth with the overnight culture, previously described, at a ratio of 1:1000 (overnight culture: Lactobacilli broth). The Lactobacilli broth culture was grown overnight at 37° C. A 10% solution of each botanical in TSB was prepared by adding either 1 ml of botanical to 9 ml TSB, or if the botanical was a solid, using 1 g of botanical and a sufficient amount of TSB to bring the total volume to 10 ml. 10% Tween® 20 stock in TSB was prepared as a positive control, by adding 1 mL Tween® 20 to 9 ml of TSB.
  • The next day, the optical density (650 nm) of the Lactobacilli broth culture was read. 1 OD is approximately, 1×109 cells/ml. The culture was centrifuged at 5,000×g for 10 minutes to pellet the bacteria. The bacteria were resuspended in a sufficient amount of TSB, so that the final concentration of bacteria was 1×106 cells/ml. 50 μl of either the 10% botanical stock or the control solution was added to wells containing the synthetic skin substrate. 50 μl of the bacteria in Lactobacilli broth was then added to each of these wells, and the cells were allowed to adhere to the synthetic skin for three hours at either 33° C. or 37° C. After three hours, the solutions were removed from the wells, and the synthetic skin was washed in the wells three times with a solution of 250 μl of PBS plus 0.05% Tween® 20. The skin was transferred to a white plate, and 200 μl of 10% AlamarBlue® dye in TSB was added to each well. The plate was incubated at 37° C. AlamarBlue® levels were read (emission levels read at 590 nm) in an Ascent plate reader (excitation level of 544 nm) at 2 and 3 hours. When not being read, the plate was incubated at 37° C. with a lid.
  • Results are given in Table 1, which is described in Example 3.
  • Example 5 Adhesion Assay for Candida albicans
  • Each of the compounds listed in Table 1 was screened to measure the effect of the compound on the adhesion of C. albicans to the skin. The protocol described herein can also be applied to test the effect of botanical compounds on the adhesion of other yeast to the skin.
  • Two days prior to the screen, a culture of C. albicans was prepared. One frozen bead of C. albicans (ATCC #10231) was added to 10 ml Saboraud's dextrose broth (“SDB”), and grown overnight at 37° C. with agitation at 150 rpm. A synthetic skin substrate (VITRO-SKIN® substrate) was placed in a hydration chamber overnight.
  • One day prior to the screen, discs of the synthetic skin, sized to fit the wells of a 96 well plate, were cut out in a controlled humidity room using a #2 tool. The discs were placed in the wells of the plate, and the plate was stored in a humidity chamber. A SDB culture was prepared by inoculating SDB with the overnight culture, previously described, at a ratio of 1:1000 (overnight culture:SDB). The SDB culture was then grown overnight at 37° C. with agitation at 150 rpm. A 10% solution of each botanical in TSB was prepared by adding either 1 ml of botanical to 9 ml TSB, or if the botanical was a solid, using 1 g of botanical and a sufficient amount of TSB to bring the total volume to 10 ml. 10% Tween® 20 stock in TSB was prepared as a positive control, by adding 1 mL of Tween® 20 to 9 ml of TSB.
  • The next day, the optical density (650 nm) of the SDB culture was read. It was assumed that 1 OD equals 1×108 cells/ml. The culture was centrifuged at 5,000×g for 10 minutes to pellet the yeast. The yeast were resuspended in a sufficient amount of TSB, so that the final concentration of yeast was 1×106 cells/ml. 50 μl of either the 10% botanical stock or the control solution was added to the wells containing the synthetic skin substrate. 50 μl of the yeast in TSB was then added to each of these wells, and the cells were allowed to adhere to the synthetic skin for three hours at 33° C., shaking slowly. After three hours, the solutions were removed from the wells, and the syntehtic skin was washed in the wells three times with a solution of 250 μl of PBS plus 0.05% Tween® 20. The skin was transferred to a white plate, and 200 μl of 10% AlamarBlue® dye in TSB was added to each well. The plate was incubated at 37° C. AlamarBlue® levels were read (emission levels read at 590 nm) in an Ascent plate reader (excitation level of 544 nm) at 2 and 3 hours. When not being read, the plate was incubated at 37° C. with a lid.
  • Results are given in Table 1, which is described in Example 3.
    TABLE 1
    Effect of Botanical Compounds on Attachment of C. albicans
    (CA), P. aeruginosa (PA), P. mirabilis (PM), S. epidermidis
    (SE), and L. acidophilus (LA) to Skin
    Botanical Compound PM PA SE CA LA
    Aloe Ferox HS 18.3 119.5 14.9 13.7 244.2
    Aloe Gel 100.7 150.5 82.6 98.2 581.7
    American Ginseng 124.3 83.9 80.6 42.2 370.3
    Angelica Root PE 4:1 225.3 119.1 257.1 7.4 141.9
    Arkin Special 131.6 92.9 25.3 29.1 146.4
    Arnica MCF 1157 Hydro 267.5 109.0 129.9 65.1 55.1
    Biodynes TRF Improved 172.2 56.1 192.0 80.0 116.2
    Bleuet MCF 783 Hydro 69.1 125.0 242.9 76.7 56.1
    Butcher's Broom 74.3 124.1 114.7 156.1 133.0
    Calendula (Marigold) 66.5 86.9 55.8 69.1 1106.8
    Calendula MCF 774 152.3 141.0 61.8 112.2 166.5
    Canadian Willowherb 46.8 103.7 4.9 152.8 3176.7
    Cat's Claw 24.1 153.5 15.3 55.6 1161.7
    Centella 141.6 123.5 90.2 190.0 857.0
    Chamomile 162.8 75.2 46.1 84.8 398.5
    Chamomile CL 52.4 127.1 48.2 151.3 147.1
    Chamomile Distillate 86.7 174.6 81.0 78.0 132.8
    Chlorella 168.6 132.6 51.3 95.9 69.4
    Ceramide Complex 52.8 37.6 58.3 145.7 1772.7
    Comfey Leaves 98.8 88.4 46.5 14.3 168.1
    Cromoist 0-25 108.0 147.9 60.0 101.2 317.6
    Cromoist HYA 41.8 105.7 11.6 77.0 291.0
    Dandelion 75.0 93.0 61.2 74.7 187.3
    Devil's Claw 82.8 141.4 32.1 79.5 755.9
    Dong Quai 81.6 121.4 90.0 32.4 750.8
    Drago-Oat Active 90.8 87.7 70.6 55.7 468.4
    Echinacea Dry Aq. 4.8 0.6 41.4 21.8 1575.5
    Gingko Biloba 19.4 92.4 22.2 108.2 614.6
    Ginseng GR 471 Hydro 107.1 144.0 57.6 130.3 385.9
    Glucosamine 99 79.0 61.0 62.3 13.9 170.3
    Goldenseal 88.8 99.2 16.9 5.5 954.0
    Gotu Kola PG 5:1 94.1 135.1 26.1 63.8 268.6
    Grape Seed 86.3 91.6 58.6 8.3 2072.4
    Grape Seed Extract 2.2 −0.9 22.7 28.3 −14.8
    Green Tea 0.5 37.7 8.0 4.9 405.3
    Green Tea Conc. 113.3 87.6 141.7 22.3 −312.9
    Green Tea Extr. −0.6 2.0 77.5 10.9 116.86
    Green Tea HS 28.5 82.3 53.1 20.8 136.24
    Hexaplant Richter 73.6 73.9 142.0 67.8 111.64
    Hydrocotyle GR 040 83.4 65.3 155.3 105.9 86.82
    Hydrolactin 2500 10.1 91.2 180.0 120.4 60.89
    Hydrolite-5 9.2 5.1 141.5 3.9 169.66
    Hydrosoy 2000 SF 44.2 73.2 38.8 68.1 383.10
    Lamier Blanc MCF 796 97.3 78.2 147.0 116.7 95.76
    Lavendar MCF 1484 97.9 81.7 224.7 48.8 45.91
    Lime Blossom 60.5 64.0 198.3 50.4 12.62
    Lime Blossom Distillate 90.0 101.5 241.0 73.2 27.30
    Marigold (Calendula) 53.1 89.6 199.5 52.9 67.22
    Marron D'Inde MCF 27.5 104.3 37.3 33.3 59.91
    1972
    Marron D'Inde (Horse 5.9 113.7 21.0 48.9 193.37
    Chestnut)
    Matricaire (German 113.9 101.6 158.5 215.2 83.4
    Chamomile)
    Melilot GR 436 91.7 93.2 123.6 205.9 168.0
    Milk Thistle 100.7 65.2 52.7 145.6 163.0
    Nab Willowbark Extr. 60.7 6.3 80.9 117.7 685.1
    NSLE Lipomicron 18.8 17.9 109.6 94.8 110.2
    Phytexcell Arnica 142.0 102.5 207.0 286.6 95.1
    Phytexcell Mulberry 87.2 88.6 88.7 135.3 57.3
    Pineapple B 7.6 1.3 2.7 16.4 −3.7
    Purple Coneflower 136.7 60.5 96.4 173.5 35.7
    Sage CL 53.9 57.9 84.2 68.2 82.0
    Sage GW 73.0 64.7 108.7 86.9 83.5
    Sage Special 118.3 73.1 153.0 58.3 112.1
    Sandal Complex 14.8 5.9 56.3 18.4 140.8
    Sapoinaire LC 386 102.5 118.0 138.2 181.0 91.3
    Sea Parsley 87.9 150.0 69.3 86.8 1506.8
    Sedaplant Richter 120.0 138.0 152.8 260.5 1304.3
    Soluble Wheat Protein 80.9 21.7 28.6 38.8 216.9
    Spirulina 142.6 123.7 58.9 127.5 1769.5
    St. John's Wort W/S 65.1 138.9 19.3 77.5 704.3
    White Mistle Toe 96.7 116.6 49.5 100.8 896.8
    Witchhazel CL 50.2 145.5 59.5 246.0 4045.1
    Witchhazel Distillate 117.4 120.4 109.3 117.2 624.8
    Witchhazel GW −24.1 116.2 124.5 65.5 1220.1
    Yarrow 160.6 145.8 34.2 91.5 750.8
    Yucca 70 13.6 0.4 26.5 0.6 3574.7
    Yucca Extr. Powder 50% 16.1 27.0 58.3 14.3 906.1
  • TABLE 2
    Effect of Selected Botanical Compounds on the Growth of C.
    albicans (CA), P. aeruginosa (PA), P. mirabilis (PM), and S.
    epidermidis (SE) (IC50 values)
    Botanical Compound CA PA PM SE
    Aloe Ferox HS   >10%   8.30%   5.00%
    American Ginseng   >10%
    Angelica Root PE 4:1   7.90%
    Arkin Special   >10%   >10%
    Canadian Willowherb   4.70%   4.70%
    Cat's Claw   >10%   >10%
    Chamomile   >10%
    Chamomile CL   4.90%
    Ceramide Complex   >10%
    Comfey Leaves   6.10%   >10%
    Cromoist HYA   >10%   7.30%
    Devil's Claw   >10%
    Dong Quai   >10%
    Echinacea Dry Aq.   2.50%   5.80%   5.80%   5.30%
    Gingko Biloba   3.30%   >10%
    Glucosamine 99   1.90%
    Goldenseal 1.8%   1.80%
    Gotu Kola PG 5:1   >10%
    Grape Seed   >10%
    Grape Seed Extract   0.20%   0.30%   0.20%   0.40%
    Green Tea   3.50%   >10%   >10%   3.80%
    Green Tea Conc.   0.30%
    Green Tea Extr.   0.10%   1.80%   >10%
    Green Tea HS   >10%   >10%
    Hydrolactin 2500   >10%
    Hydrolite-5   8.30%   2.20%   2.00%
    Hydrosoy 2000 SF   >10%   >10%
    Lavendar MCF 1484   >10%
    Marron D'Inde MCF   >10%   >10%   >10%
    1972
    Marron D'Inde (Horse   >10%   >10%   >10%
    Chestnut)
    Nab Willowbark Extr.   9.60%
    NSLE Lipomicron   6.00%   5.40%
    Pineapple B   >10%   8.10%   >10%   1.30%
    Sandal Complex   >10%   9.70%   >10%
    Soluble Wheat Protein   >10%   9.80%   >10%
    St. John's Wort W/S   >10%
    White Mistle Toe   >10%
    Witchhazel GW   >10%
    Yarrow   >10%
    Yucca 70   8.20%   >10%   1.80%   6.40%
    Yucca Extr. Powder 50%   7.70%   >10%   >10%
  • TABLE 3
    Source of Botanical Compounds
    Name Company Address Lot Catalog
    Aloe Ferox HS Alban Muller Northvale, 7114158 64453
    International NJ
    Aloe Gel Tri-K Northvale, 970217
    Industries NJ
    Amercian Bio-botanica Hauppauge, 951340 9865
    Ginseng NY
    Angelica Root Bio-botanica Hauppauge, 921653 401250
    PE 4:1 NY
    Apple GT Dragoco Totowa, NJ 2/037050 L742477
    Arkin Special Dragoco Totowa, NJ 2/032581 L647147
    Arnica MCF Gattefosse Cedex, France 23043 5005
    1157 Hydro
    Amica Special Dragoco Totowa, NJ 2/034591 L641060
    Avocado Dragoco Totowa, NJ 2/034599 L645246
    AVocado GW Dragoco Totowa, NJ 2/031170 L603922
    Biodynes TRF Brooks South 3965
    Improved Industries Plainfield, NJ
    Black Currant Dragoco Totowa, NJ 2/036100 P331166
    B
    Black Currant Dragoco Totowa, NJ 2/037100 P331166
    GT
    Bleuet MCF Gattefosse, Cedex, France 23593 5009
    783 Hydro
    (cornflower)
    Butcher's Alban Muller Northvale, NJ 8025951 66363
    Broom HS International
    Calendula Bell Flavors Northbrook, IL Req:
    (Marigold) & Fragrances, 062169
    Inc.
    Calendula Gattefose Cedex, France 24243 5015
    MCF 774
    Hydro
    Canadian Fytokem Saskatoon, 971015-P
    Willowherb Canada
    Cat's Claw Bio-botanica Hauppauge, 951341 9945A
    NY
    Centella Bio-botanica Hauppauge, 981177 9869A
    NY
    Ceramide Chemisches Berlin 732207
    Complex Cir Laboratorium
    Chamomile Bio-botanica Hauppauge, 980572 9831
    NY
    Chamomile CL Dragoco Totowa, NJ 2/033026 L659226
    Chamomile Dragoco Totowa, NJ 2/380930 L659743
    Distillate
    Chamomile Dragoco Totowa, NJ 2/033021 694633
    Special
    Chlorella Bio-botanica Hauppauge, 951289 9835
    NY
    Comfrey Bell Flavors Northbrook, IL Req:
    Leaves & Fragrances, 062565
    Inc.
    Cranberry B Dragoco Totowa, NJ 2/036600 P15193
    Cranberry GT Dragoco Totowa, NJ 2/037600 4100723
    Crolastin Croda Parsippany, NJ 0526
    Cromoist 0-25 Croda Parsippany, NJ 8172
    (Hydrolyzed
    whole oats)
    Cromoist Hya Croda Parsippany, NJ 7922/1
    Dandelion Active S72041A 816310-
    organics 11
    Devil's Claw Indena- Uppersaddle EG522
    International River,
    Sourcing NJ
    Dong Quai Active Lewisville, TX S64418B 316320-
    organics 11
    Glenn Corp.
    Drago-Oat- Dragoco Totowa, NJ 2/060900 25493
    Active
    Echinacea Dry MMP, Inc. 7329
    Aqueous Ext
    Garcinia Bio-botanica Hauppauge, 951283 9861
    NY
    Ginkgo Biloba Bio-botanica Hauppauge, 951286 9861A
    NY
    Ginseng GR Gattefosse Cedex, France 23268 5030
    471 Hydro
    Glucosamine Sher-Mar San Diego, CA
    99 Enterprises
    Goldenseal Bio-botanica Hauppauge, 951338 9868
    NY
    Gotu Kola PG Bio-botanica Hauppauge,
    5:1 NY
    Grape Seed Active Lewisville, TX S76920B 318650-
    organics 11
    Glenn Corp.
    Grape Seed Dragoco Totowa, NJ 2/03199 P17400
    Extract
    Grapefruit B Dragoco Totowa, NJ 2/036150 L4100313
    Grapefruit GT Dragoco Totowa, NJ 2/037150 L4100211
    Green Tea Bio-botanica Hauppauge, 9945
    NY
    Green Tea Active Lewisville, TX 308463 300230-
    Conc. organics 94
    Glenn Corp.
    Green Tea Dragoco Totowa, NJ 2/031598 3066
    Extract
    Green Tea HS Alban Muller Northvale, NJ 7114309
    International
    Hexaplant Chemisches Berlin 732431 243
    Richter Laboratorium
    Hibiscus Dragoco Totowa, NJ 2/033115 L851028
    Special
    Hydrocotyle Gattefosse Cedex, France 22842 5038
    GR 040 Hydro
    (hydrocotyl)
    Hydrolactin Croda Parsippany, NJ 7034D
    2500
    Hydrolite-5 Dragoco Totowa, NJ 2/016020 27033
    Hydrosoy 2000 Croda Parsippany, NJ 1278
    S.F.
    Lamier Blanc Gattefosse Cedex, France 22571 5040
    MCF 796
    Hydro (White
    Nettle)
    Lavener MCF Gattefosse Cedex, France 25872
    1484 Hydro
    Lime Blossom Dragoco Totowa, NJ 2/033093 L644049
    CL
    Lime Blossom Dragoco Totowa, NJ 2/382920 L659568
    Distillate
    Lys MCF 1968 Gattefosse Cedex, France 23410 5044
    Hydro (lily)
    Marigold Bell Flavors Northbrook, IL 62565 B-2924
    (Calendula) & Fragrances,
    Inc.
    Marron D'Inde Gattefosse Cedex, France 22043 5046
    MCF 1972
    Hydro (Horse
    Chestnut)
    Marronnier Indea- Uppersaddle EG042
    D'Inde (Horse International River, NJ
    Chestnut) Sourcing
    Matricaire Indea- Uppersaddle EG004
    (German International River, NJ
    Chamomille) Sourcing
    Melilot GR Gattefosse Cedex, France 23316 5051
    436 Hydro
    (Sweet
    Clover)
    Milk Thistle Active Lewisville, TX S76894A 344000-
    organics 11
    Glen Corp.
    Nab Willow Brooks South 28392
    Bark Extract Industries Plainfield, NJ
    NSLE Sederma France NSLE1032
    Lipomicron
    Orange B Dragoco Totowa, NJ 2/036400 P327911
    Organe GT Dragoco Totowa, NJ 2/037400 P327911
    Papaya B Dragoco Totowa, NJ 2/036450 L8102475
    Phytexcell Croda Parsippany, NJ 972 34656
    Amica
    Phytexcell Croda Parsippany, NJ 1004 34684
    Mulberry
    Phytoplenolin Bio-botanica Hauppauge, 980510 9870
    NY
    Pineapple B Dragoco Totowa, NJ 2/036000 728754
    Purple Bio-botanica Hauppauge, 951338 9852
    Coneflower NY
    Sage CL Dragoco Totowa, NJ 2/033294 L640225
    Sage GW Dragoco Totowa, NJ 2/031770 L619604
    Sage Special Dragoco Totowa, NJ 2/033291 P312506
    Sandal Dragoco Totowa, NJ 2/B04081 132360
    Complex
    Saponaire LC Gattefosse Cedex, France 24418 5070
    386 Hydro
    (Saponaria)
    Sea Parsley Phillip A81 R10418
    rockley, Ltd.
    Sedaplant Chemisches Berlin 732384 460
    Richter Laboratorium
    Soluble Wheat Croda Parsippany, NJ 0017
    Proten
    (tritisol)
    Spirulina Bio-botanica Hauppauge, 951288 9837
    NY
    St. John's Dragoco Totowa, NJ 2/032985 L658926
    Wort W/S
    White Mistle Dragoco Totowa, NJ 2/033141 L653324
    Toe
    Witchhazel CL Dragoco Totowa, NJ 2/033900 723422
    Witchhazel Dragoco Totowa, NJ 2/365470 L638489
    Distillate
    Witchhazel Dragoco Totowa, NJ 2/031340 L651033
    GW
    Yarrow Bio-botanica Hauppauge, 951336 9958
    NY
    Yucca 70 Sher-Mar San Diego, CA
    Enterprises
    Yucca Extract Garuda Santa Cruz, 557- YUCEXT50
    Ca
    Powder (50%) 98226-DE

Claims (102)

1. A product for promoting the adherence of Lactobacillus acidophilus to the surface of skin or mucosa, the product comprising a substrate and a botanical compound capable of increasing the adherence of Lactobacillus acidophilus to the surface of skin or mucosa by at least about 50%.
2. The product as set forth in claim 1, wherein the product is a wipe comprising a fibrous wipe substrate.
3. The product as set forth in claim 1, wherein the product is an absorbent article comprising an absorbent substrate.
4. The product as set forth in claim 1 wherein the botanical compound is selected from the group consisting of Aloe Ferox HS, Ginseng, Calendula (Marigold), Ceramide Complex, Comfey Leaves, Cromoist 0-25, Cromoist HYA, Dandelion, Devil's Claw, Dong Quai, Drago-Oat Active, Echinacea, Gingko Biloba, Glucosamine, Goldenseal, Gotu Kola, Grape Seed, Green Tea, Hydrolite-5, Hydrosoy 2000 SF, Horse Chestnut, Milk Thistle, Willowbark, Soluble Wheat Protein, Spirulina, St. John's Wort, White Mistle Toe, Witchhazel, and Yucca.
5. The product as set forth in claim 1 wherein the botanical compound is selected from the group consisting of Aloe Ferox HS, American Ginseng, Calendula (Marigold), Ceramide Complex, Comfey Leaves, Cromoist 0-25, Cromoist HYA, Dandelion, Devil's Claw, Dong Quai, Drago-Oat Active, Echinacea Dry Aq., Gingko Biloba, Ginseng GR 471 Hydro, Glucosamine 99, Goldenseal, Gotu Kola PG 5:1, Grape Seed, Green Tea, Hydrolite-5, Hydrosoy 2000 SF, Marron D'Inde (Horse Chestnut), Milk Thistle, Nab Willowbark Extr., Soluble Wheat Protein, Spirulina, St. John's Wort W/S, White Mistle Toe, Witchhazel Distillate, Witchhazel GW, Yucca 70, and Yucca Extr. Powder 50%.
6. The product as set forth in claim 1 wherein the botanical compound is selected from the group consisting of Calendula (Marigold), Ceramide Complex, Echinacea Dry Aq., Grape Seed, Spirulina, Witchhazel GW, and Yucca 70.
7. The product as set forth in claim 1 wherein the botanical compound is selected from the group consisting of Aloe Ferox HS, American Ginseng, Calendula (Marigold), Ceramide Complex, Comfey Leaves, Cromoist 0-25, Cromoist HYA, Dandelion, Devil's Claw, Dong Quai, Drago-Oat Active, Ginseng GR 471 Hydro, Glucosamine 99, Gotu Kola PG 5:1, Grape Seed, Hydrolite-5, Hydrosoy 2000 SF, Marron D'Inde (Horse Chestnut), Milk Thistle, Soluble Wheat Protein, Spirulina, Witchhazel Distillate, and Witchhazel GW.
8. The product as set forth in claim 1 wherein the product is a feminine wipe, feminine napkin, tampon, or interlabial pad.
9. The wipe as set forth in claim 2 wherein the wipe is a dry wipe and the botanical compound is present in an amount of from about 0.01% (by weight of the treated substrate) to about 50% (by weight of the treated substrate).
10. The wipe as set forth in claim 2 wherein the wipe further comprises a liquid formulation.
11. The wipe as set forth in claim 10 wherein the botanical compound is present in the liquid formulation in an amount of from about 0.01% (by total weight of the liquid formulation) to about 50% (by total weight of the liquid formulation).
12. A product for promoting the adherence of Staphlococcus epidermidis to the surface of skin, the product comprising a substrate and a botanical compound capable of increasing the adherence of Staphlococcus epidermidis to the surface of skin by at least about 50%.
13. The product as set forth in claim 12, wherein the product is a wipe comprising a fibrous wipe substrate.
14. The product as set forth in claim 12, wherein the product is an absorbent article comprising an absorbent substrate.
15. The product as set forth in claim 12 wherein the botanical compound is selected from the group consisting of Bleuet MCF 783 Hydro, Hydrocotyle GR 040, Hydrolactin 2500, Lavendar MCF 1484, Lime Blossom, Lime Blossom Distillate, Marigold (Calendula), and Sage Special.
16. The product as set forth in claim 12 wherein the botanical compound is selected from the group consisting of Bleuet MCF 783 Hydro, Hydrocotyle GR 040, Hydrolactin 2500, Marigold (Calendula), and Sage Special.
17. The wipe as set forth in claim 13 wherein the wipe is a dry wipe and the botanical compound is present in an amount of from about 0.01% (by weight of the treated substrate) to about 50% (by weight of the treated substrate).
18. The wipe as set forth in claim 13 wherein the wipe further comprises a liquid formulation.
19. The wipe as set forth in claim 18 wherein the botanical compound is present in the liquid formulation in an amount of from about 0.01% (by total weight of the liquid formulation) to about 50% (by total weight of the liquid formulation).
20. A product for inhibiting the adherence of Candida albicans to the surface of skin or mucosa, the product comprising a substrate and a botanical compound capable of inhibiting the adherence of Candida albicans to the surface of skin or mucosa by at least about 50%.
21. The product as set forth in claim 20, wherein the product is a wipe comprising a fibrous wipe substrate.
22. The product as set forth in claim 20, wherein the product is an absorbent article comprising an absorbent substrate.
23. The product as set forth in claim 20 wherein the botanical compound is selected from the group consisting of Ginseng, Glucosamine, and Yucca.
24. The product as set forth in claim 20 wherein the botanical compound is selected from the group consisting of Aloe Ferox HS, American Ginseng, Arkin Special, Comfey Leaves, Dong Quai, Echinacea Dry Aq., Glucosamine 99, Goldenseal, Grape Seed, Grape Seed Extr., Green Tea, Green Tea Conc., Green Tea Extr., Green Tea HS, Hydrolite-5, Lavendar MCF 1484, Marron D'Inde MCF 1972, Marron D'Inde (Horse Chestnut), Pineapple B, Sandal Complex, Soluble Wheat Protein, Yucca 70, and Yucca Extr. Powder 50%.
25. The product as set forth in claim 20 wherein the botanical compound is selected from the group consisting of Aloe Ferox HS, Comfey Leaves, Glucosamine 99, Goldenseal, Grape Seed, Green Tea, Green Tea Extr., Hydrolite-5, Pineapple B, Sandal Complex, Yucca 70, and Yucca Extr. Powder 50%.
26. The product as set forth in claim 20 wherein the botanical compound is selected from the group consisting of Aloe Ferox HS, American Ginseng, Comfey Leaves, Dong Quai, Glucosamine 99, Grape Seed, Green Tea Conc., Hydrolite-5, Lavendar MCF 1484, Marron D'Inde MCF 1972, Marron D'Inde (Horse Chestnut), Pineapple B, Sandal Complex, and Soluble Wheat Protein.
27. The wipe as set forth in claim 21 wherein the wipe is a dry wipe and the botanical compound is present in an amount of from about 0.01% (by weight of the treated substrate) to about 50% (by weight of the treated substrate).
28. The wipe as set forth in claim 21 wherein the wipe further comprises a liquid formulation.
29. The wipe as set forth in claim 28 wherein the botanical compound is present in the liquid formulation in an amount of from about 0.01% (by total weight of the liquid formulation) to about 50% (by total weight of the liquid formulation).
30. A product for inhibiting the adherence of Proteus mirabilis to the surface of skin or mucosa, the product comprising a substrate and a botanical compound capable of inhibiting the adherence of Proteus mirabilis to the surface of skin or mucosa by at least about 50%.
31. The product as set forth in claim 30, wherein the product is a wipe comprising a fibrous wipe substrate.
32. The product as set forth in claim 30, wherein the product is an absorbent article comprising an absorbent substrate.
33. The product as set forth in claim 30 wherein the botanical compound is selected from the group consisting of Echinacea, Witchhazel, and Yucca.
34. The product as set forth in claim 30 wherein the botanical compound is selected from the group consisting of Aloe Ferox HS, Cromoist HYA, Echinacea Dry Aq., Gingko Biloba, Grape Seed Extr., Green Tea, Green Tea Extr., Green Tea HS, Hydrolactin 2500, Hydrolite-5, Hydrosoy 2000 SF, Marron D'Inde (Horse Chestnut), Marron D'Inde MCF 1972, NSLE Lipomicron, Pineapple B, Sandal Complex, Witchhazel GW, Yucca 70, and Yucca Exr. Powder 50%.
35. The product as set forth in claim 30,wherein the botanical compound is selected from the group consisting of Aloe Ferox HS, Echinacea Dry Aq., Gingko Biloba, Grape Seed Extr., Green Tea, Green Tea Extr., Hydrolactin 2500, Hydrolite-5, Marron D'Inde (Horse Chestnut), NSLE Lipomicron, Pineapple B, Sandal Complex, Witchhazel GW, Yucca 70, and Yucca Extr. Powder 50%.
36. The product as set forth in claim 30 wherein the botanical compound is selected from the group consisting of Aloe Ferox HS, Hydrolactin 2500, Hydrolite-5, Marron D'Inde (Horse Chestnut), Pineapple B, Sandal Complex, and Witchhazel 5 GW.
37. The wipe as set forth in claim 31 wherein the wipe is a dry wipe and the botanical compound is present in an amount of from about 0.01% (by weight of the treated substrate) to about 50% (by weight of the treated substrate).
38. The wipe as set forth in claim 31 wherein the wipe further comprises a liquid formulation.
39. The wipe as set forth in claim 38 wherein the botanical compound is present in the liquid formulation in an amount of from about 0.01% (by total weight of the liquid formulation) to about 50% (by total weight of the liquid formulation).
40. A product for inhibiting the adherence of Pseudomonas aeruginosa to the surface of skin or mucosa, the product comprising a substrate and a botanical compound capable of inhibiting the adherence of Pseudomonas aeruginosa to the surface of skin or mucosa by at least about 50%.
41. The product as set forth in claim 40, wherein the product is a wipe comprising a fibrous wipe substrate.
42. The product as set forth in claim 40, wherein the product is an absorbent article comprising an absorbent substrate.
43. The product as set forth in claim 40 wherein the botanical compound is selected from the group consisting of Ceramide Complex, Echinacea Dry Aq., Grape Seed Extr., Green Tea, Green Tea Extr., Hydrolite-5, Nab Willowbark Extr., NSLE Lipomicron, Pineapple B, Sandal Complex, Soluble Wheat Protein, Yucca 70, and Yucca Extr. Powder 50%.
44. The product as set forth in claim 40 wherein the botanical compound is selected from the group consisting of Ceramide Complex, Hydrolite-5, NSLE Lipomicron, Pineapple B, Sandal Complex, and Soluble Wheat Protein.
45. The wipe as set forth in claim 41 wherein the wipe is a dry wipe and the botanical compound is present in an amount of from about 0.01% (by weight of the treated substrate) to about 50% (by weight of the treated substrate).
46. The wipe as set forth in claim 41 wherein the wipe further comprises a liquid formulation.
47. The wipe as set forth in claim 46 wherein the botanical compound is present in the liquid formulation in an amount of from about 0.01% (by total weight of the liquid formulation) to about 50% (by total weight of the liquid formulation).
48. A product for inhibiting the adherence of Staphlococcus epidermidis to the surface of skin, the product comprising a substrate and a botanical compound capable of inhibiting the adherence of Staphlococcus epidermidis to the surface of skin by at least about 50%.
49. The product as set forth in claim 48, wherein the product is a wipe comprising a fibrous wipe substrate.
50. The product as set forth in claim 48, wherein the product is an absorbent article comprising an absorbent substrate.
51. The product as set forth in claim 48 wherein the botanical compound is selected from the group consisting of Aloe Ferox HS, Arkin Special, Comfey Leaves, Cromoist HYA, Devil's Claw, Echinacea Dry Aq., Gingko Biloba, Goldenseal, Gotu Kola PG 5:1, Grape Seed Extr., Green Tea, Hydrosoy 2000 SF, Marron D'Inde (Horse Chestnut), Marron D'Inde MCF 1972, Pineapple B, Soluble Wheat Protein, St. John's Wort W/S, White Mistle Toe, and Yucca 70.
52. The product as set forth in claim 48 wherein the botanical compound is selected from the group consisting of Aloe Ferox HS, Comfey Leaves, Cromoist HYA, Devil's Claw, Gotu Kola PG 5:1, Hydrosoy 2000 SF, Marron D'Inde (Horse Chestnut), Marron D'Inde MCF 1972, Pineapple B, and Soluble Wheat Protein.
53. The wipe as set forth in claim 49 wherein the wipe is a wound care wipe.
54. The wipe as set forth in claim 49 wherein the wipe is a dry wipe and the botanical compound is present in an amount of from about 0.01% (by weight of the treated substrate) to about 50% (by weight of the treated substrate).
55. The wipe as set forth in claim 49 wherein the wipe further comprises a liquid formulation.
56. The wipe as set forth in claim 55 wherein the botanical compound is present in the liquid formulation in an amount of from about 0.01% (by total weight of the liquid formulation) to about 50% (by total weight of the liquid formulation).
57. A product for inhibiting the growth of Candida albicans on or around the skin surface, the product comprising a substrate and a botanical compound, wherein the botanical compound has an IC50 value of about 5% or less for Candida albicans.
58. The product as set forth in claim 57, wherein the product is a wipe comprising a fibrous wipe substrate.
59. The product as set forth in claim 57, wherein the product is an absorbent article comprising an absorbent substrate.
60. The product as set forth in claim 57, wherein the botanical compound is selected from the group consisting of Echinacea Dry Aq., Glucosamine 99, Goldenseal, Grape Seed Extr., Green Tea, Green Tea Conc., and Green Tea Extr.
61. The product as set forth in claim 57 wherein the botanical compound is selected from the group consisting of Glucosamine 99 and Green Tea Conc.
62. The wipe as set forth in claim 58 wherein the wipe is a dry wipe and the botanical compound is present in an amount of from about 0.01% (by weight of the treated substrate) to about 50% (by weight of the treated substrate).
63. The wipe as set forth in claim 58 wherein the wipe further comprises a liquid formulation.
64. The wipe as set forth in claim 63 wherein the botanical compound is present in the liquid formulation in an amount of from about 0.01% (by total weight of the liquid formulation) to about 50% (by total weight of the liquid formulation).
65. A product for inhibiting the growth of Proteus mirabilis on or around the skin surface, the product comprising a substrate and a botanical compound, wherein the botanical compound has an IC50 value of about 5% or less for Proteus mirabilis.
66. The product as set forth in claim 65 wherein the product is a wipe comprising a fibrous wipe substrate.
67. The product as set forth in claim 65 wherein the product is an absorbent article comprising an absorbent substrate.
68. The product as set forth in claim 65 wherein the botanical compound is selected from the group consisting of Gingko Biloba, Grape Seed Extr., Hydrolite-5, and Yucca 70.
69. The product as set forth in claim 65 wherein the botanical compound is Hydrolite-5.
70. The wipe as set forth in claim 66 wherein the wipe is a dry wipe and the botanical compound is present in an amount of from about 0.01% (by weight of the treated substrate) to about 50% (by weight of the treated substrate).
71. The wipe as set forth in claim 66 wherein the wipe further comprises a liquid formulation.
72. The wipe as set forth in claim 71 wherein the botanical compound is present in the liquid formulation in an amount of from about 0.01% (by total weight of the liquid formulation) to about 50% (by total weight of the liquid formulation).
73. A product for inhibiting the growth of Pseudomonas aeruginosa on or around the skin surface, the product comprising a substrate and a botanical compound, wherein the botanical compound has an IC50 value of about 5% or less for Pseudomonas aeruginosa.
74. The product as set forth in claim 73 wherein the product is a wipe comprising a fibrous wipe substrate.
75. The product as set forth in claim 73 wherein the product is an absorbent article comprising an absorbent substrate.
76. The product as set forth in claim 73 wherein the botanical compound is selected from the group consisting of Grape Seed Extr., Green Tea Extr., and Hydrolite-5.
77. The product as set forth in claim 73 wherein the botanical compound is Hydrolite-5.
78. The wipe as set forth in claim 74 wherein the wipe is a dry wipe and the botanical compound is present in an amount of from about 0.01% (by weight of the treated substrate) to about 50% (by weight of the treated substrate).
79. The wipe as set forth in claim 74 wherein the wipe further comprises a liquid formulation.
80. The wipe as set forth in claim 79 wherein the botanical compound is present in the liquid formulation in an amount of from about 0.01% (by total weight of the liquid formulation) to about 50% (by total weight of the liquid formulation).
81. A product for inhibiting the growth of Staphlococcus epidermidis on or around the skin surface, the product comprising a substrate and a botanical compound, wherein the botanical compound has an IC50 value of about 5% or less for Staphlococcus epidermidis.
82. The product as set forth in claim 81 wherein the product is a wipe comprising a fibrous wipe substrate.
83. The product as set forth in claim 81 wherein the product is an absorbent article comprising an absorbent substrate.
84. The product as set forth in claim 81 wherein the botanical compound is selected from the group consisting of Aloe Ferox HS, Goldenseal, Grape Seed Extr., Green Tea, and Pineapple B.
85. The product as set forth in claim 81 wherein the botanical compound is selected from the group consisting of Aloe Ferox HS, and Pineapple B.
86. The wipe as set forth in claim 82 wherein the wipe is used for wound care.
87. The wipe as set forth in claim 82 wherein the wipe is a dry wipe and the botanical compound is present in an amount of from about 0.01% (by weight of the treated substrate) to about 50% (by weight of the treated substrate).
88. The wipe as set forth in claim 82 wherein the wipe further comprises a liquid formulation.
89. The wipe as set forth in claim 88 wherein the botanical compound is present in the liquid formulation in an amount of from about 0.01% (by total weight of the liquid formulation) to about 50% (by total weight of the liquid formulation).
90. A product for inhibiting the growth of at least one problem flora on or around the skin surface, the problem flora selected from the group consisting of Proteus mirabilis, Pseudomonas aeruginosa, and Candida albicans, wherein the product comprises a substrate and a botanical compound, the botanical compound selected from the group consisting of Green Tea Extr., Hydrolite-5, Sandal Complex, and Yucca Extr. Powder 50%.
91. The product as set forth in claim 90, wherein the product is a wipe comprising a fibrous wipe substrate.
92. The product as set forth in claim 90, wherein the product is an absorbent article comprising an absorbent substrate.
93. The product as set forth in claim 90 wherein the botanical compound is selected from the group consisting of Hydrolite-5 and Sandal Complex.
94. The wipe as set forth in claim 91 wherein the wipe is a dry wipe and the botanical compound is present in an amount of from about 0.01% (by weight of the treated substrate) to about 50% (by weight of the treated substrate).
95. The wipe as set forth in claim 91 wherein the wipe further comprises a liquid formulation.
96. The wipe as set forth in claim 95 wherein the botanical compound is present in the liquid formulation in an amount of from about 0.01% (by total weight of the liquid formulation) to about 50% (by total weight of the liquid formulation).
97. A product for selectively controlling the balance of flora on the skin, the product comprising:
a) a substrate selected from the group consisting of a fibrous wipe substrate and an absorbent substrate;
b) a first botanical compound that promotes the adherence of Lactobacillus acidophilus to the surface of skin or mucosa, the first botanical compound being capable of increasing the adherence of Lactobacillus acidophilus to the surface of skin or mucosa by at least about 50%; and
c) a second botanical compound that inhibits the adherence of at least one organism to the surface of skin or mucosa, the organism selected from the group consisting of (i) Candida albicans, (ii) Proteus mirabilis, (iii) Pseudomonas aeruginosa, and (iv) Staphylococcus epideriidis, wherein the second botanical compound is capable of inhibiting the adherence of the organism to the surface of skin or mucosa by at least about 50%.
98. The product as set forth in claim 97 further comprising a third botanical compound that inhibits the growth of at least one organism on or around the skin surface, the organism selected from the group consisting of (i) Candida albicans, (ii) Proteus mirabilis, (iii) Pseudomonas aeruginosa, and (iv) Staphylococcus epidermidis, wherein the third botanical compound has an IC50 value of about 5% or less for Candida albicans, Proteus mirabilis, Pseudomonas aeruginosa, or Staphylococcus epidermidis.
99. A product for selectively controlling the balance of flora on the skin, the product comprising:
a) a substrate selected from the group consisting of a fibrous wipe substrate and an absorbent substrate;
b) a first botanical compound that promotes the adherence of Lactobacillus acidophilus to the surface of skin or mucosa, the first botanical compound being capable of increasing the adherence of Lactobacillus acidophilus to the surface of skin or mucosa by at least about 50%; and
c) a second botanical compound that promotes the adherence of Staphylococcus epidermidis to the surface of skin, the second botanical compound being capable of increasing the adherence of Staphylococcus epidermidis to the surface of skin by at least about 50%.
100. The product as set forth in claim 99 further comprising a third botanical compound that inhibits the adherence of at least one organism to the surface of skin or mucosa, the organism selected from the group consisting of (i) Candida albicans, (ii) Proteus miirabilis, and (iii) Pseudomonas aeruginosa, wherein the third botanical compound is capable of inhibiting the adherence of the organism to the surface of skin or mucosa by at least about 50%.
101. The product as set forth in claim 100, further comprising a fourth botanical compound that inhibits the growth of at least one organism on or around the skin surface, the organism selected from the group consisting of (i) Candida albicans, (ii) Proteus mirabilis, and (iii) Pseudomonas aeruginosa, wherein the fourth botanical compound has an IC50 value of about 5% or less for Candida albicans, Proteus mirabilis, or Pseudomonas aeruginosa.
102. A product for selectively controlling the balance of flora on the skin, the product comprising:
(a) a substrate selected from the group consisting of a fibrous wipe substrate and an absorbent substrate;
(b) a first botanical compound that inhibits the adherence of at least one organism to the surface of skin or mucosa, the organism selected from the group consisting of (i) Candida albicans, (ii) Proteus mirabilis, (iii) Pseudomonas aeruginosa, and (iv) Staphylococcus epidermidis, wherein the first botanical compound is capable of inhibiting the adherence of the organism to the surface of skin or mucosa by at least about 50%; and
(c) a second botanical compound that inhibits the growth of at least one organism on or around the skin surface, the organism selected from the group consisting of Candida albicans, Proteus mirabilis, Pseudomonas aeruginosa, and Staphylococcus epidermidis, wherein the second botanical compound has an IC50 value of about 5% or less for Candida albicans, Proteus mirabilis, Pseudomonas aeruginosa, or Staphylococcus epideriidis.
US10/624,186 2003-07-22 2003-07-22 Wipe and methods for improving skin health Abandoned US20050019379A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US10/624,186 US20050019379A1 (en) 2003-07-22 2003-07-22 Wipe and methods for improving skin health

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US10/624,186 US20050019379A1 (en) 2003-07-22 2003-07-22 Wipe and methods for improving skin health
MXPA06000318A MXPA06000318A (en) 2003-07-22 2004-04-08 Wipe and methods for improving skin health.
KR1020067000309A KR101159857B1 (en) 2003-07-22 2004-04-08 Wipe and Methods for Improving Skin Health
PCT/US2004/011052 WO2005016300A2 (en) 2003-07-22 2004-04-08 Wipe and methods for improving skin health
EP04749954A EP1653916A2 (en) 2003-07-22 2004-04-08 Wipe and methods for improving skin health
US11/176,060 US8846116B2 (en) 2003-07-22 2005-07-07 Wipe and methods for improving skin health
US14/465,941 US10022308B2 (en) 2003-07-22 2014-08-22 Wipe and methods for improving skin health

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US11/176,060 Continuation US8846116B2 (en) 2003-07-22 2005-07-07 Wipe and methods for improving skin health

Publications (1)

Publication Number Publication Date
US20050019379A1 true US20050019379A1 (en) 2005-01-27

Family

ID=34079944

Family Applications (3)

Application Number Title Priority Date Filing Date
US10/624,186 Abandoned US20050019379A1 (en) 2003-07-22 2003-07-22 Wipe and methods for improving skin health
US11/176,060 Active 2025-11-19 US8846116B2 (en) 2003-07-22 2005-07-07 Wipe and methods for improving skin health
US14/465,941 Active 2025-11-29 US10022308B2 (en) 2003-07-22 2014-08-22 Wipe and methods for improving skin health

Family Applications After (2)

Application Number Title Priority Date Filing Date
US11/176,060 Active 2025-11-19 US8846116B2 (en) 2003-07-22 2005-07-07 Wipe and methods for improving skin health
US14/465,941 Active 2025-11-29 US10022308B2 (en) 2003-07-22 2014-08-22 Wipe and methods for improving skin health

Country Status (5)

Country Link
US (3) US20050019379A1 (en)
EP (1) EP1653916A2 (en)
KR (1) KR101159857B1 (en)
MX (1) MXPA06000318A (en)
WO (1) WO2005016300A2 (en)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050087317A1 (en) * 2003-10-28 2005-04-28 Little Rapids Corporation Dispersable wet wipe
WO2006113475A2 (en) * 2005-04-15 2006-10-26 North Carolina State University Methods and compositions to modulate adhesion and stress tolerance in bacteria
US20080221710A1 (en) * 2006-10-13 2008-09-11 General Electric Company System and methods for reducing an effect of a disturbance
US20090155325A1 (en) * 2007-12-14 2009-06-18 Kimberly-Clark Worldwide, Inc. Formulation and products for promoting skin cleanliness and health
FR2948022A1 (en) * 2009-07-08 2011-01-21 Raymonde Anna Marthe Gennequin Natural cosmetic product obtained by mixing and boiling horse chestnut, agar-agar, apple alcohol, lemon essential oil, orange essential oil, mandarin essential oil and water
US20150329798A1 (en) * 2012-12-27 2015-11-19 Kimberly-Clark Worldwide, Inc. Water Soluble Essential Oils and Their Use

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070298085A1 (en) * 2006-06-27 2007-12-27 Lestage David J Skin Sanitizing Object
CA2662116C (en) * 2006-08-29 2013-03-26 Playtex Products, Inc. Tampon removal device
US8920911B2 (en) 2011-03-04 2014-12-30 The Procter & Gamble Company Web substrates having wide color gamut indicia printed thereon
US8985013B2 (en) 2011-03-04 2015-03-24 The Procter & Gamble Company Apparatus for applying indicia having a large color gamut on web substrates
US8839716B2 (en) 2011-03-04 2014-09-23 The Procter & Gamble Company Apparatus for applying indicia having a large color gamut on web substrates
US8616126B2 (en) 2011-03-04 2013-12-31 The Procter & Gamble Company Apparatus for applying indicia having a large color gamut on web substrates
US8839717B2 (en) 2011-03-04 2014-09-23 The Procter & Gamble Company Unique process for printing multiple color indicia upon web substrates
US8943959B2 (en) 2011-03-04 2015-02-03 The Procter & Gamble Company Unique process for printing multiple color indicia upon web substrates
US8927092B2 (en) 2011-03-04 2015-01-06 The Procter & Gamble Company Web substrates having wide color gamut indicia printed thereon
US8927093B2 (en) 2011-03-04 2015-01-06 The Procter & Gamble Company Web substrates having wide color gamut indicia printed thereon
US8943957B2 (en) 2011-03-04 2015-02-03 The Procter & Gamble Company Apparatus for applying indicia having a large color gamut on web substrates
US8943958B2 (en) 2011-03-04 2015-02-03 The Procter & Gamble Company Apparatus for applying indicia having a large color gamut on web substrates
US8962124B2 (en) 2011-03-04 2015-02-24 The Procter & Gamble Company Web substrates having wide color gamut indicia printed thereon
US8943960B2 (en) 2011-03-04 2015-02-03 The Procter & Gamble Company Unique process for printing multiple color indicia upon web substrates
US8665493B2 (en) 2011-03-04 2014-03-04 The Procter & Gamble Company Web substrates having wide color gamut indicia printed thereon
US8758560B2 (en) 2011-03-04 2014-06-24 The Procter & Gamble Company Web substrates having wide color gamut indicia printed thereon
US8916260B2 (en) 2011-03-04 2014-12-23 The Procter & Gamble Company Web substrates having wide color gamut indicia printed thereon
US8833250B2 (en) 2011-03-04 2014-09-16 The Procter & Gamble Company Apparatus for applying indicia having a large color gamut on web substrates
US8916261B2 (en) 2011-03-04 2014-12-23 The Procter & Gamble Company Web substrates having wide color gamut indicia printed thereon
US8858213B2 (en) 2013-02-22 2014-10-14 The Procter & Gamble Company Equipment and processes for the application of atomized fluid to a web substrate
US10060062B2 (en) 2013-02-22 2018-08-28 The Procter & Gamble Company Equipment and processes for the application of atomized fluid to a web substrate
US9085130B2 (en) 2013-09-27 2015-07-21 The Procter & Gamble Company Optimized internally-fed high-speed rotary printing device
US9694380B2 (en) 2014-05-30 2017-07-04 The Procter & Gamble Company Customizable apparatus and method for transporting and depositing fluids
US9937704B2 (en) 2014-05-30 2018-04-10 The Procter & Gamble Company Method for making a customizable apparatus for transporting and depositing fluids
US9724908B2 (en) 2014-05-30 2017-08-08 The Procter & Gamble Company Customizable apparatus and method for printing fluids
US9694379B2 (en) 2014-05-30 2017-07-04 The Procter & Gamble Company Customizable apparatus and method for transporting and depositing fluids
US9724907B2 (en) 2014-05-30 2017-08-08 The Procter & Gamble Company Customizable apparatus and method for printing fluids
US9259911B2 (en) 2014-05-30 2016-02-16 The Procter & Gamble Company Customizable apparatus and method for transporting and depositing fluids
US9492835B2 (en) 2014-05-30 2016-11-15 The Procter & Gamble Company Customizable apparatus and method for transporting and depositing fluids
EP3148806B1 (en) 2014-05-30 2019-04-10 The Procter and Gamble Company Customizable apparatus and method for transporting and depositing fluids
WO2017004045A1 (en) 2015-06-29 2017-01-05 The Procter & Gamble Company Customizable apparatus and method for transporting and depositing fluids
US10286095B2 (en) 2015-09-11 2019-05-14 Olson Ip Technologies, Inc. Travel kit
US10144016B2 (en) 2015-10-30 2018-12-04 The Procter & Gamble Company Apparatus for non-contact printing of actives onto web materials and articles
WO2017156209A1 (en) 2016-03-11 2017-09-14 The Procter & Gamble Company Compositioned, textured nonwoven webs
WO2018184048A1 (en) 2017-04-03 2018-10-11 Lenzing Ag A nonwoven web designed for use as a wipes substrate
WO2018184047A1 (en) 2017-04-03 2018-10-11 Lenzing Ag A nonwoven web designed for use in a healthcare wiper

Citations (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4100324A (en) * 1974-03-26 1978-07-11 Kimberly-Clark Corporation Nonwoven fabric and method of producing same
US4255337A (en) * 1978-09-08 1981-03-10 Givaudan Corporation Novel odorants and flavorants
US4609547A (en) * 1980-04-15 1986-09-02 Beecham Group P.L.C. Anti-allergic compositions and their use
US5141803A (en) * 1988-06-29 1992-08-25 Sterling Drug, Inc. Nonwoven wipe impregnating composition
US5152996A (en) * 1990-12-10 1992-10-06 Eastman Kodak Company Nonwoven wipes impregnated with an aqueous solution of a zinc acetate peroxide and a surfactant
US5472700A (en) * 1993-10-20 1995-12-05 Fmc Corporation Combinations of neem seed extract and bifenthrin for control of ectoparasites on animals
US5587358A (en) * 1994-05-09 1996-12-24 Asahi Kasei Kogyo Kabushiki Kaisha Potentiators of antimicrobial activity
US5601833A (en) * 1993-12-30 1997-02-11 L'oreal Protective, nutritive and/or firming composition for the simultaneous treatment of the surface layers and deep layers of the skin, and use thereof
US5604262A (en) * 1995-03-22 1997-02-18 Research Corporation Technologies, Inc. Topical antimicrobial agents
US5648083A (en) * 1995-02-10 1997-07-15 The Procter & Gamble Company Personal care compositions and wipe products containing the compositions
US5656278A (en) * 1993-09-30 1997-08-12 The Boots Company Plc Dermatological and cosmetic compositions
US5723138A (en) * 1996-05-02 1998-03-03 Bae; Jae-Hyun Skin-adhesive cosmetics for removing wrinkles, containing vitamins and aloe extract
US5804168A (en) * 1997-01-29 1998-09-08 Murad; Howard Pharmaceutical compositions and methods for protecting and treating sun damaged skin
US5830916A (en) * 1996-05-23 1998-11-03 Duke University Inhibitor of ceramidase
US5888524A (en) * 1995-11-01 1999-03-30 Kimberly-Clark Worldwide, Inc. Antimicrobial compositions and wet wipes including the same
US5906992A (en) * 1996-11-21 1999-05-25 Colgate Palmolive Company Foam cleaning compositions
US5916573A (en) * 1995-08-21 1999-06-29 Spiers; Samantha M. Topical treatment of the skin with a grapeseed oil composition
US5935596A (en) * 1997-03-20 1999-08-10 Chesebrough-Pond's Usa Co. Delivery of skin benefit agents via adhesive strips
US6028018A (en) * 1996-07-24 2000-02-22 Kimberly-Clark Worldwide, Inc. Wet wipes with improved softness
US6060075A (en) * 1997-08-27 2000-05-09 Vittal Mallya Scientific Research Foundation Check mite composition and a process for preparing the same
US6159487A (en) * 1998-03-24 2000-12-12 Chesebrough-Pond's Usa Co., Division Of Conopco, Inc. Moistened cosmetic eye treatment fads
US6174519B1 (en) * 1997-12-24 2001-01-16 Shaklee Corporation Composition for protecting skin from damaging effects of ultraviolet light
US6228265B1 (en) * 1996-01-11 2001-05-08 Digestco Limited Bio-enhancer
US6235737B1 (en) * 2000-01-25 2001-05-22 Peter Styczynski Reduction of hair growth
US6258355B1 (en) * 1996-11-22 2001-07-10 Vsl Pharmaceuticals Inc. Sphingomyelinase compositions and use thereof
US6280758B1 (en) * 1997-11-12 2001-08-28 The Procter & Gamble Company Low-pH, acid-containing personal care compositions which exhibit reduced sting
US20020022043A1 (en) * 1999-12-28 2002-02-21 Miller Jeffrey D. Method for killing house dust mites in clothing and other soft materials
US20020136755A1 (en) * 2000-12-22 2002-09-26 Tyrrell David John Absorbent articles with non-aqueous compositions containing botanicals
US20030120228A1 (en) * 2001-12-20 2003-06-26 Koenig David W. Absorbent article

Family Cites Families (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1984002845A1 (en) * 1983-01-21 1984-08-02 Advanced Drug Tech Vitamin-containing skin care ointment
JPS59166585A (en) 1983-03-10 1984-09-19 Osaka Chem Lab Antioxidant
US5043155A (en) * 1988-02-10 1991-08-27 Richardson-Vicks Inc. Emulsifying compositions including amphipathic emulsifying agents
JP2632530B2 (en) 1988-02-15 1997-07-23 ワコー樹脂株式会社 Plastic film packaging materials excellent in freshness and deodorant
JPH01228325A (en) 1988-03-09 1989-09-12 Fujitsu Ltd Digital phase locked loop circuit
US4941995A (en) 1988-07-05 1990-07-17 Scott Paper Company Natural preservative composition for wet wipes
JP3019325B2 (en) 1989-06-26 2000-03-13 エステー化学株式会社 Wet tissue
JPH0329823A (en) 1989-06-28 1991-02-07 Sumitomo Metal Ind Ltd Measuring device of emissivity of steel plate
JPH0725657B2 (en) 1990-02-09 1995-03-22 花王株式会社 Hair treatment composition
US5512283A (en) 1990-07-06 1996-04-30 Allergene, Inc. Methods for the selective suppression of an immune response to dust mite der Pi
CN1071844A (en) 1992-12-18 1993-05-12 张洪昌 Process for extracting natural biological activator from green tea
JPH07228892A (en) 1994-02-18 1995-08-29 Kao Corp Detergent composition for hard surface
AUPN056395A0 (en) 1995-01-16 1995-02-09 University Of Melbourne, The Production of genetically transformed forage grasses
JPH08217658A (en) 1995-02-15 1996-08-27 Kanebo Ltd Ceramide synthesis accelerator
JP3122333B2 (en) 1995-02-28 2001-01-09 株式会社薬理学中央研究所 Sphingomyelin and ceramide of novel manufacturing method and ceramide blending a therapeutic agent or cosmetic for the red blood cells as a starting material
JPH08268859A (en) 1995-04-03 1996-10-15 Kao Corp Cosmetic for preventing and improving wrinkle
JPH09110615A (en) 1995-10-17 1997-04-28 Mitsui Norin Kk Disinfectant containing catechins blended therein
US5753246A (en) * 1995-11-20 1998-05-19 Peters; Marlin W. Packaged germicidal towelette, sanitation kit and method for promoting hygiene
JPH09194317A (en) 1996-01-23 1997-07-29 Sumitomo Chem Co Ltd Agent for controlling house dust mite
EP0881905A1 (en) * 1996-02-14 1998-12-09 THE PROCTER & GAMBLE COMPANY Urogenital and intestinal disorder compositions comprising a substance derived from plant species of the ericaceae family and a lactic acid bacteria growth factor
TR199801613T2 (en) 1996-02-19 1998-11-23 Nycomed Imaging A/S Contrast agents or in related improvements.
JP2935663B2 (en) * 1996-05-21 1999-08-16 マイクロアルジェコーポレーション株式会社 Antibacterial sheet and its production method having biodegradability
WO1998003147A1 (en) 1996-07-24 1998-01-29 Kimberly-Clark Worldwide, Inc. Fibrous sheet materials containing oat extract
US6338855B1 (en) * 1996-10-25 2002-01-15 The Procter & Gamble Company Cleansing articles for skin and/or hair which also deposit skin care actives
GB2322300A (en) 1997-02-20 1998-08-26 Reckitt & Colman Inc Miticidal and disinfectant composition
FI970733A (en) 1997-02-21 1998-08-22 Micropulva Ltd Oy Apparatus and method for producing the ultrafine dry powders an energetic working gas by means of
US6027716A (en) 1997-04-02 2000-02-22 Farmo-Nat Ltd. Synergistic herbal extracts
BR9804814A (en) 1997-04-04 2000-01-25 Optiva Corp "Antimicrobial agents for oral hygiene products"
US5939050A (en) 1997-04-04 1999-08-17 Optiva Corp. Antimicrobial compositions
US6063387A (en) 1997-04-17 2000-05-16 Elizabeth Arden Co., Division Of Conopco, Inc. Anhydrous cosmetic composition with ceramides for firming skin
US6645506B1 (en) * 1997-04-18 2003-11-11 Ganeden Biotech, Inc. Topical compositions containing extracellular products of Pseudomonas lindbergii and Emu oil
GB2327881A (en) 1997-08-06 1999-02-10 Reckitt & Colman Inc Control of dust particles
GB2329588B (en) 1997-09-25 2002-07-31 Reckitt & Colmann Prod Ltd Deactivants for dust mite allergens
JP3928224B2 (en) 1997-10-08 2007-06-13 住友化学株式会社 Acaricidal composition
JPH11130627A (en) 1997-10-27 1999-05-18 Kayoko Handa Production and use of medicinal pack agent consisting of tea leaf fine powder and extract of powdered tea or tea as main component
JPH11139959A (en) 1997-11-10 1999-05-25 Kayoko Handa Production of skin cleaning cosmetic, facial washing preparation and soap for nutrient medicine containing vegetable tea leaf fine powder, ground green tea and tea essence, amino acid, vitamin and oligosaccharide mixed therein
EP0922457A1 (en) 1997-11-26 1999-06-16 THE PROCTER & GAMBLE COMPANY Skin protection composition
US6203797B1 (en) * 1998-01-06 2001-03-20 Stephen C. Perry Dietary supplement and method for use as a probiotic, for alleviating the symptons associated with irritable bowel syndrome
JPH11228325A (en) 1998-02-17 1999-08-24 Hiromi Nishii Liquid agent composition compounded with plant extract
JPH11292710A (en) 1998-04-03 1999-10-26 T Pooru Kk Germicidal composition
DE69905560T2 (en) 1998-04-17 2003-09-25 Rao Pillarisetti Venkata Subba Environmentally friendly acaricidal formulation
JPH11332778A (en) 1998-05-22 1999-12-07 Kao Corp Wiping sheet
DE19824683A1 (en) 1998-06-03 1999-12-09 Grewe Helmut F Use of ethereal oil in spray form for control of mites, e.g. house dust mite
DE19824727A1 (en) 1998-06-03 1999-12-09 Beiersdorf Ag Cosmetic or dermatological preparations containing catechins or green tea extract
DE19824680A1 (en) 1998-06-03 1999-12-09 Grewe Helmut F Use of ethereal oil in depot form for control of mites, e.g. house dust mite
DE19827624A1 (en) 1998-06-20 1999-12-23 Beiersdorf Ag Use of catechols or plant extracts containing them in intensifying natural skin tanning or in stimulating melanogenesis
US6319958B1 (en) 1998-06-22 2001-11-20 Wisconsin Alumni Research Foundation Method of sensitizing microbial cells to antimicrobial compound
JP4601088B2 (en) 1998-08-07 2010-12-22 ピアス株式会社 Ceramide synthesis promoter to enhance the sphingomyelinase activity
JP2000053923A (en) 1998-08-11 2000-02-22 Sekisui Chem Co Ltd Floor-polishing agent having miticidal effect
JP2000063262A (en) 1998-08-19 2000-02-29 Osaka Yakuhin Kenkyusho:Kk Antimicrobial cosmetic composition
JP3343516B2 (en) 1998-08-29 2002-11-11 株式会社大貴 Health sheets and a method of manufacturing the same
JP3816262B2 (en) 1998-09-30 2006-08-30 花王株式会社 Ceramide production promoter
FR2786694B1 (en) 1998-12-03 2002-09-27 Serobiologiques Lab Sa The use of plant extracts in particular have anti-radical action and cosmetic or dermopharmaceutical composition comprising such extracts
DE19903716A1 (en) 1999-01-30 2000-08-03 Henkel Kgaa Antioxidant skin care products
US6485756B1 (en) * 1999-04-06 2002-11-26 Collaborative Technologies, Inc. Stable, homogeneous natural product extracts containing polar and apolar fractions
WO2001000033A1 (en) 1999-06-28 2001-01-04 Ecosmart Technologies, Inc. Plant essential oils against dust mites
JP2001009950A (en) 1999-06-28 2001-01-16 Mitsubishi Chemicals Corp Air permeable laminate and sanitary article
US6506394B1 (en) 1999-06-30 2003-01-14 Kimberly-Clark Worldwide, Inc. Delivery of a botanical extract to a treated substrate for transfer to skin
AU5764800A (en) 1999-07-01 2001-01-22 Johnson & Johnson Consumer Companies, Inc. Cleansing compositions
US6410039B1 (en) 1999-09-15 2002-06-25 First Scientific, Inc. Protective topical composition, products including the same, and methods
ES2235456T3 (en) 1999-10-08 2005-07-01 Coty B.V. Cosmetic active substance preparation with a protection factor against synergistically improved radicals.
JP4139545B2 (en) 2000-03-17 2008-08-27 花王株式会社 Skin cosmetics
GB2363074B (en) 2000-04-07 2003-04-09 Reckitt Benckiser Method of deactivating dust mite allergens
JP2003531955A (en) 2000-05-04 2003-10-28 キンバリー クラーク ワールドワイド インコーポレイテッド Polymer dispersible in water with an ion-sensitive article using methods and it's production
CN1111068C (en) 2000-07-27 2003-06-11 上海北医大生物科技有限公司 Strong anti-oxidative composite capsule of grape seed extract OPC and its production method
US20020071859A1 (en) * 2000-10-23 2002-06-13 Unilever Home & Personal Care Usa, Division Of Conopco, Inc. Towelette product with sunscreen agent
US20030130636A1 (en) * 2001-12-22 2003-07-10 Brock Earl David System for improving skin health of absorbent article wearers
JPWO2004016236A1 (en) * 2002-08-14 2005-12-02 株式会社ファンケル Cosmetics
US20040096484A1 (en) 2002-11-19 2004-05-20 Tyrrell David J. Antioxidant-containing wipes and absorbent products for improving skin health
US7585518B2 (en) * 2002-11-19 2009-09-08 Kimberly-Clark Worldwide, Inc. Products and methods for maintaining or increasing ceramide levels in skin
US7357950B2 (en) * 2003-03-21 2008-04-15 Elizabeth Anne Mazzio Topical treatment for dyshidrosis (pompholyx) and dry skin disorders
US20040228811A1 (en) * 2003-05-13 2004-11-18 Kimberly-Clark Worldwide, Inc. Sunscreen wipes having high sunscreen formulation transfer rate

Patent Citations (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4100324A (en) * 1974-03-26 1978-07-11 Kimberly-Clark Corporation Nonwoven fabric and method of producing same
US4255337A (en) * 1978-09-08 1981-03-10 Givaudan Corporation Novel odorants and flavorants
US4609547A (en) * 1980-04-15 1986-09-02 Beecham Group P.L.C. Anti-allergic compositions and their use
US5141803A (en) * 1988-06-29 1992-08-25 Sterling Drug, Inc. Nonwoven wipe impregnating composition
US5152996A (en) * 1990-12-10 1992-10-06 Eastman Kodak Company Nonwoven wipes impregnated with an aqueous solution of a zinc acetate peroxide and a surfactant
US5656278A (en) * 1993-09-30 1997-08-12 The Boots Company Plc Dermatological and cosmetic compositions
US5472700A (en) * 1993-10-20 1995-12-05 Fmc Corporation Combinations of neem seed extract and bifenthrin for control of ectoparasites on animals
US5601833A (en) * 1993-12-30 1997-02-11 L'oreal Protective, nutritive and/or firming composition for the simultaneous treatment of the surface layers and deep layers of the skin, and use thereof
US5587358A (en) * 1994-05-09 1996-12-24 Asahi Kasei Kogyo Kabushiki Kaisha Potentiators of antimicrobial activity
US5648083A (en) * 1995-02-10 1997-07-15 The Procter & Gamble Company Personal care compositions and wipe products containing the compositions
US5604262A (en) * 1995-03-22 1997-02-18 Research Corporation Technologies, Inc. Topical antimicrobial agents
US5916573A (en) * 1995-08-21 1999-06-29 Spiers; Samantha M. Topical treatment of the skin with a grapeseed oil composition
US5888524A (en) * 1995-11-01 1999-03-30 Kimberly-Clark Worldwide, Inc. Antimicrobial compositions and wet wipes including the same
US6228265B1 (en) * 1996-01-11 2001-05-08 Digestco Limited Bio-enhancer
US5723138A (en) * 1996-05-02 1998-03-03 Bae; Jae-Hyun Skin-adhesive cosmetics for removing wrinkles, containing vitamins and aloe extract
US5830916A (en) * 1996-05-23 1998-11-03 Duke University Inhibitor of ceramidase
US5851782A (en) * 1996-05-23 1998-12-22 Duke University Inhibitors of ceramidase
US6028018A (en) * 1996-07-24 2000-02-22 Kimberly-Clark Worldwide, Inc. Wet wipes with improved softness
US5906992A (en) * 1996-11-21 1999-05-25 Colgate Palmolive Company Foam cleaning compositions
US6258355B1 (en) * 1996-11-22 2001-07-10 Vsl Pharmaceuticals Inc. Sphingomyelinase compositions and use thereof
US5804168A (en) * 1997-01-29 1998-09-08 Murad; Howard Pharmaceutical compositions and methods for protecting and treating sun damaged skin
US5935596A (en) * 1997-03-20 1999-08-10 Chesebrough-Pond's Usa Co. Delivery of skin benefit agents via adhesive strips
US5985300A (en) * 1997-03-20 1999-11-16 Chesebrough-Pond's Usa Co. Delivery of skin benefit agents via adhesive strips
US6060075A (en) * 1997-08-27 2000-05-09 Vittal Mallya Scientific Research Foundation Check mite composition and a process for preparing the same
US6280758B1 (en) * 1997-11-12 2001-08-28 The Procter & Gamble Company Low-pH, acid-containing personal care compositions which exhibit reduced sting
US6174519B1 (en) * 1997-12-24 2001-01-16 Shaklee Corporation Composition for protecting skin from damaging effects of ultraviolet light
US6235272B1 (en) * 1997-12-24 2001-05-22 Shaklee Corporation Composition for protecting skin from damaging effects of ultraviolet light
US6159487A (en) * 1998-03-24 2000-12-12 Chesebrough-Pond's Usa Co., Division Of Conopco, Inc. Moistened cosmetic eye treatment fads
US20020022043A1 (en) * 1999-12-28 2002-02-21 Miller Jeffrey D. Method for killing house dust mites in clothing and other soft materials
US6235737B1 (en) * 2000-01-25 2001-05-22 Peter Styczynski Reduction of hair growth
US20020136755A1 (en) * 2000-12-22 2002-09-26 Tyrrell David John Absorbent articles with non-aqueous compositions containing botanicals
US20030120228A1 (en) * 2001-12-20 2003-06-26 Koenig David W. Absorbent article

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050087317A1 (en) * 2003-10-28 2005-04-28 Little Rapids Corporation Dispersable wet wipe
WO2006113475A2 (en) * 2005-04-15 2006-10-26 North Carolina State University Methods and compositions to modulate adhesion and stress tolerance in bacteria
US20060269998A1 (en) * 2005-04-15 2006-11-30 North Carolina State University Methods and compositions to modulate adhesion and stress tolerance in bacteria
WO2006113475A3 (en) * 2005-04-15 2007-03-29 Eric Altermann Methods and compositions to modulate adhesion and stress tolerance in bacteria
EP2302032A1 (en) * 2005-04-15 2011-03-30 North Carolina State University Methods and compositions to modulate adhesion and stress tolerance in bacteria
US20080221710A1 (en) * 2006-10-13 2008-09-11 General Electric Company System and methods for reducing an effect of a disturbance
US20090155325A1 (en) * 2007-12-14 2009-06-18 Kimberly-Clark Worldwide, Inc. Formulation and products for promoting skin cleanliness and health
FR2948022A1 (en) * 2009-07-08 2011-01-21 Raymonde Anna Marthe Gennequin Natural cosmetic product obtained by mixing and boiling horse chestnut, agar-agar, apple alcohol, lemon essential oil, orange essential oil, mandarin essential oil and water
US20150329798A1 (en) * 2012-12-27 2015-11-19 Kimberly-Clark Worldwide, Inc. Water Soluble Essential Oils and Their Use

Also Published As

Publication number Publication date
US8846116B2 (en) 2014-09-30
US10022308B2 (en) 2018-07-17
EP1653916A2 (en) 2006-05-10
WO2005016300A3 (en) 2005-04-21
KR101159857B1 (en) 2012-06-25
US20140363485A1 (en) 2014-12-11
MXPA06000318A (en) 2006-03-28
WO2005016300A2 (en) 2005-02-24
KR20060036440A (en) 2006-04-28
US20060008514A1 (en) 2006-01-12

Similar Documents

Publication Publication Date Title
EP0999745B1 (en) Anti-bacterial/anti-viral coatings, coating process and parameters thereof
EP0817876B1 (en) Premoistened, flushable, disposable and biodegradable wet wipes
CA2322461C (en) Proton donating actives in absorbent articles
EP1455722B2 (en) System for skin health of absorbent article wearers
US5334388A (en) Antimicrobial drying substrate
US8309788B2 (en) Protease inhibitors in absorbent articles
ES2255730T3 (en) Utilization topical spore probiotic bacillus to prevent or treat microbial infections.
US6503525B1 (en) Absorbent article which maintains or improves skin health
DE60023919T2 (en) Improved topical compositions having extracellular products of probiotic bacteria and uses thereof
US5871763A (en) Substrate treated with lotion
US6207596B1 (en) Disposable premoistened wipe containing an antimicrobial protease inhibitor
US20020128615A1 (en) Absorbent articles with non-aqueous compositions containing anionic polymers
US6217890B1 (en) Absorbent article which maintains or improves skin health
JP4161023B2 (en) The absorbent article
Hauman et al. Biocompatibility of dental materials used in contemporary endodontic therapy: a review. Part 1. Intracanal drugs and substances
US20070087744A1 (en) Method for reducing the time delay in a telephone system
AU2009220859B2 (en) Moisturizing hand sanitizer
US20100262097A1 (en) Delivery Device
AU2002314714B2 (en) Antimicrobial formulations
JP4522700B2 (en) Sanitary napkin having a hydrophobic lotion
US5512199A (en) Hand wipe solution
AU707468B2 (en) Non-aqueous emollient iodophor formulations
EP1492577B1 (en) Film-forming compositions for protecting skin from body fluids and articles made therefrom
KR101643779B1 (en) Formulation and Products for Promoting Skin Cleanliness and Health
FI107019B (en) Additives feminine hygiene products

Legal Events

Date Code Title Description
AS Assignment

Owner name: KIMBERLY-CLARK WORLDWIDE, INC., WISCONSIN

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:LANGE, BETH A.;KOENIG, DAVID W.;SCHNEIDER, CHRISTINE L.;REEL/FRAME:014900/0321

Effective date: 20030814

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION